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ABSTRACT OF DISSERTATION

DEVELOPMENT OF A ROBUST LINAC-BASED RADIOSURGERY PROGRAM
FOR MULTIPLE BRAIN METASTASES & ESTIMATION THE
RADIOBIOLOGICAL RESPONSE OF INDIRECT CELL KILL
Accurate and precise delivery of Stereotactic Radiosurgery (SRS) using Gamma
Knife (GK) unit by Leksell is a gold standard for multiple intracranial lesions. SRS
provides less brain toxicity compared to whole brain radiotherapy techniques historically
used. However, these treatments are limited in availability and are accompanied by long
treatment times with painful, intolerable headframe fixation. With advancements in linear
accelerator (Linac) based SRS, multiple brain lesions can be treated separately with
individual isocenters or, more recently, altogether with a single isocenter multi-target
(SIMT) volumetric modulated arc therapy (VMAT) technique. SIMT methods reduce the
challenges of treating patients with GK by significantly decreasing treatment times,
improving patient comfort and clinic workflow. This dissertation explores the usability of
SIMT VMAT and presents potential solutions to the challenges of treating multiple brain
lesions using Linac-based SRS.
Treating multiple brain lesions simultaneously with a SIMT VMAT plan is an
efficient treatment option for SRS; however, it does not account for patient setup
uncertainty, which degrades treatment delivery accuracy. This dissertation quantifies the
loss of target coverage by simulating patient setup errors that would be seen on daily cone
beam CT imaging during patient set up and verification. These simulations resulted in
dosimetric discrepancies up to 70% (average, 30%), providing suboptimal SRS treatments.
It was also found that small tumors were more susceptible to these setup uncertainties and
would experience greater losses of target coverage. This means SIMT-VMAT, in its
current use, is not an accurate SRS treatment modality for brain metastases. This
dissertation aims to provide potential solutions to minimize these spatial uncertainties
discussed. First, a novel risk-adapted correction strategy was explored where dose is
escalated for small targets at a large distance from the isocenter. These treatments with up
to ±1o/1 mm set up errors in all 6-directions demonstrated promising plan quality and

treatment delivery accuracy with less spread of intermediate dose to the normal brain.
Second, a dual isocenter planning strategy that groups lesions based on brain hemisphere
location was proposed. These plans provided similar target coverage and dose conformity
as compared to the SIMT plans with less low and intermediate dose to the brain and less
dose to surrounding critical organs. These techniques could potentially improve target
localization accuracy and be delivered within a standard treatment slot.
Though these SIMT VMAT treatments for multiple brain metastases could be at
risk of detrimental spatial uncertainties, recent clinical outcome studies suggest high rates
of tumor local-control and positive treatment outcomes. In this dissertation, this is
explained through a combination of both direct and indirect cell kill. A single dose of 15
Gy or more will cause damage to the weak cellular vasculature of the brain tumors,
ultimately resulting in secondary cell death. By inducing clinically observable systematic
set up errors, the role of secondary cell death is modeled to define the relationship between
achieving required target coverage and spatial uncertainty. For 20 Gy prescription, it was
found that patient set up errors of 1.3 mm/1.3°in all 6-directions must be maintained in
order to achieve a target dose of 15 Gy or higher with no additional brain toxicity. At this
range of uncertainty, devascularization would occur resulting in positive tumor local
control, providing guidance to treating physicians for clinically acceptable patient setup
errors and perhaps resulting acceptable treatment outcomes. A prospective clinical trial is
necessary to further validate this radiobiological model, incorporating secondary cell death
with direct cell kill using a single-isocenter VMAT plan for multiple brain lesions.
KEYWORDS: Single Isocenter VMAT, Patient Setup Errors, Multiple Brain Metastases,
Stereotactic Radiosurgery, Indirect Cell Kill
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CHAPTER 1. INTRODUCTION
1.1

An Overview of Brain Metastases
Multiple brain metastases are common, occurring in 20-40% of cancer patients.1

The development of multiple brain metastases usually indicate a poor overall prognosis of
a patient.2 There is potential for serious complications due to the neurologic symptoms they
cause and can result in death by compression of the normal brain against the nonexpendable
skull.3 Presenting symptoms depend on the surrounding anatomic structures of the lesions.
Symptoms range from a minor as a headache or cognitive dysfunction to hemorrhaging,
resulting in comas or neurological seemingly stroke-like complications.3
Posner and Chernik produced a comprehensive study at Memorial Sloan-Kettering
Cancer Center (New York, USA) performing 2375 brain autopsies in the 1970’s. Lung
cancer was found to be the most common primary malignancy occurring in 18 to 63% of
the cases studied. Other cancers with potential development of brain metastases included
breast (2 to 21%), melanoma (4 to 16%), and colorectal cancers (2 to 11%).4 Brain
metastases are diagnosed with contrast-enhanced magnetic resonance imaging (MRI),
though, with an unknown primary malignancy a pathology report via biopsy is necessary
for confirming the diagnosis.1 In the MRI scans, gadolinium-based contrast agents are used
to highlight the brain metastases through disruption of the blood-brain barrier.
To maximize survival benefits, prognostic factors must be assessed where both
demographic and clinical variables are involved. These factors include age, Karnofsky
Performance Status (KPS) score, number of brain metastases, primary tumor type and
systemic activity.5 The highest determinant for survival is treatment regimen and KPS
score as second. KPS score is an indication of how sickly and capable a patient is to care
1

for themselves. These factors were categorized with a Radiation Therapy Oncology Group
(RTOG) database using recursive partitioning analysis (RPA). The RPA class combined
with course of treatment is used to estimate median survival.5 Through history,
improvements have been made in the diagnosis and treatment of brain metastases to better
prognosis. This topic is still the forefront of research to best manage these patients giving
the longest and most quality life that medicine can provide.

1.2

Treatment of Multiple Brain Metastases
Historically, multiple brain metastases have been treated with whole brain

radiotherapy (WBRT). With this treatment technique, survival increased by median 3-4
months, which is an increase from the 1-month survival without treatment.5 Tumor
response is found in approximately 60% of patients where symptom maintenance occurs
at the same rate, though is vaguely studied.6-7Fractionation schemes for the WBRT
treatments are employed to best limit risk of neurotoxicity. Most commonly 30 to 35 Gy
in 10 to 14 fractions is delivered.2 WBRT, currently, is mostly reserved for patients with
multiple brain metastases who do not qualify for surgical resection or stereotactic
radiosurgery (SRS). The risk for neurotoxicity resulting in complications like memory loss
makes it a non-ideal method for treating multiple brain metastases.
With the increased availability of imaging techniques, the use of surgery for
resection of brain metastases became a primary treatment option for one or two brain
metastases. Surgery can be beneficial for rapid relief or neurological symptoms and can
establish local tumor control.8 Surgery is of very limited use for patients with multiple brain
metastases and is limited to dominant, symptomatic or life-threatening lesions.5 Only a
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highly selected group of patients with a few metastases are able to benefit from surgical
resection. Instead, SRS is a noninvasive (or minimally invasive) treatment option for
multiple brain metastases, even for tumors unable to be removed surgically.
SRS delivers a single, high dose of radiation to a small tumor volume using multiple
converging beams. There are multiple modes of SRS delivery with frame-based Gamma
Knife (GK), cone or MLC based linear accelerators (Linacs) and cyclotron proton beams.
According to RTOG 90-05 protocol, maximum tolerable prescription doses of 15 to 24 Gy
are used based on increasing tumor size and location.9 One-year local control rates range
from 71 to 79% for single-lesion and multiple brain metastases. Larger tumor sizes
(generally > 3 cm in diameter) are not ideal candidates for single dose brain SRS due to
increased risk of brain radionecrosis.
Chemotherapy mostly plays a limited role for treatment of brain metastases and is
mostly reserved for patients that have failed other treatment options. The amount of the
chemotherapy drug to pass the blood brain barrier is difficult to estimate.10 There are also
treatment options that are a combination of these methods. Surgery followed by WBRT to
single brain metastases found to have better local control rates but no benefit to overall
survival, though they were less likely to die of neurologic causes.11 SRS boost to residual
tumors after WBRT is a treatment option to improve local control, but have shown no effect
on overall survival benefits.12 The same result was evident for SRS to brain lesions
followed by WBRT.13 WBRT still presents concern with dose to brain resulting in
radionecrosis. This is apparent in a randomized trial performed by MD Anderson Cancer
Center (Houston, TX) on SRS of multiple brain metastases patients. They compared SRS
patients with and without WBRT. Patients that received WBRT in addition to SRS
3

demonstrated inferior neurocognitive results compared to those that did not receive WBRT.
This must be considered when determining the best treatment option for multiple brain
metastases on a per patient basis.14

1.3

Modes of SRS to Brain Metastases
SRS to multiple brain metastases offers a precise and accurate delivery of a single

large dose of radiation to small tumor volumes and provide better local control rates. The
patient is positioned with very high precision using headframe fixation or a tight maskbased system. Treatment delivery accuracy is of paramount importance for the patient
safety. It provides a concentrated dose in the lesion with steep dose gradients outside of the
tumor volume in an effort to spare adjacent critical organs. There is a wide array of modes
used for SRS of multiple brain tumors including x-rays, gamma rays and proton beams.
SRS was first introduced by a neurosurgeon, Lars Leksell in 1951 (in Sweden).15
To this day, GK SRS is considered the gold standard for treating intracranial lesions. It
consists of 192 Co-60 sources in a hemispherical orientation and are collimated to focus at
a single point at the target. It requires stereotactic head frame fixation to prevent patient
motion in order to localize the target accurately.16 In GK SRS, dose is prescribed to the
50% isodose line, providing it a high hotspot in the center of a lesion with a high dose falloff outside the target, sparing adjacent critical organs and normal brain. This gives GK the
advantage of having a high biological effective dose (BED) to the tumor. Though there are
benefits of high local control when using GK SRS, there are some issues to consider. GK
SRS is not readily available to all patients, where it is only included in 26% of all 428
dedicated SRS systems in the United States of America.17 The treatment times of this

4

technique are long with painful, intolerable headframe fixation, where patients with large
or multiple craniotomy sites are often not qualified. Those with superficial tumors would
also not qualify due to collision issues. Coordination with anesthesiologists is required for
the patients who may not tolerate headframe fixation. Lastly, because of it is a Co-60 unit,
it requires more stringent radiation safety program in placed with tighter regulatory
requirements and specialized manpower. These challenges along with the supporting
evidence of SRS outcomes has stimulated the development of new treatment technologies
to bring these treatments to more clinics around the globe.
Linac-based SRS has been of interest due to its availability in many radiation
therapy centers. A recent treatment unit is CyberKnife (Accuray Inc., Sunnyvale, CA) used
for radiosurgery of both intracranial and extracranial lesions. It is a compact linear
accelerator mounted to an arm that can move in all 6 degrees of freedom (6DOF), although
no posterior beams are available. Pencil beams of radiation are delivered as the robotic arm
moves around the patient. This treatment method also has even longer treatment times than
that of GK SRS.18 Ring mounted linear accelerators, specifically helical Tomotherapy
(Accuray Inc., Sunnyvale, CA) have also been investigated in the treatment of multiple
brain metastases. With this technique, a fan beam of radiation rotates around the patient in
a helical path. In addition to co-planner beam geometry, this technique still had less ideal
treatment times, though less than that of GK and CyberKnife SRS. With coplanar beam
geometry, a conformal dose to the target was possible, however dose fall-off outside of the
target was not clinically optimal.19
C-arm Linac-based SRS to multiple brain metastases began with the use of dynamic
conformal arcs (DCA)-based treatment plans. This method is useful for treating small
5

lesions where cones or multileaf collimators (MLC) are used to conform to the target and
move dynamically with gantry rotation at different couch positions.20 With this original
DCA method, the isocenter was placed at the center of each lesion with each target being
treated separately. Treatment planning and delivery were based on the number of lesions
present and number of arcs used per lesion. Multiple isocenter DCA methods was followed
by the use of intensity modulated arc therapy (IMRT) treatment. This method uses multiple
non-coplanar static beams with MLC modulation for each treatment field. MLC positions
are optimized with inverse planning methods. In inverse planning approaches, many
control points are created and an iterative least squares algorithm is used to generate a
fluence map at each point, optimizing the MLC positions.21 IMRT methods created a more
conformal dose distribution than that of DCA, but with the trade-off of low dose spread
and relatively longer treatment times.22 Later, volumetric modulated arc therapy (VMAT)
was introduced where gantry speed, MLC aperture and dose rate varied during treatment
delivery.23, 24 VMAT planning uses an inverse optimization technique similar to IMRT,
though the solution is the optimization of MLC aperture rather than fluence maps. MLC
position adjustments along with gantry rotation and dose rate variability are used to
generate a highly conformal dose distribution.21 VMAT was developed to achieve the same
coverage as IMRT with reduced treatment times due to a decrease in total monitor units
(MU). VMAT also has fewer couch kicks are required with less intermediate dose spread.25
Traditionally, VMAT methods were developed to treat tumors individually, similar
to DCA or IMRT methods, where there was a single isocenter per target. With multiple
isocenter methods, the patient is aligned to each isocenter and therefore each lesion is
imaged, matched and treated seperately.26 Because of these long treatment times, it has
6

been of great interest to evaluate the feasibility of a single isocenter, treating multiple
lesions simultaneously with a single VMAT plan. Single isocenter multi target (SIMT)
methods have several variations. Huang et al. developed a single isocenter DCA-based
radiosurgery technique for multiple brain metastases using high-definition MLC.27 This
was adopted by Brainlab (Feldkirchen, Germany) for multi-lesion treatments and
commercially known as Multiple Metastases Elements (MME) in BrainLab treatment
planning system (TPS). Alternatively, VMAT planning approaches use a multi-arc, noncoplanar geometry with a single isocenter placed at the center of all targets. VMAT
optimization is then used as described above. Varian adopted this methodology and
automated the treatment planning and delivery process as a new module in the Eclipse TPS
(Varian Medical Systems, version 15.6, Palo Alto, CA) known as HyperArc VMAT.16 This
method automates the isocenter placement at the geometric center of all lesions and
chooses the best collimator angles to each arc to reduce dose to the normal brain. HyperArc
VMAT is frameless, user and patient friendly and simplifies the treatment planning and
delivery.28, 29 There is also a new option to use a hybrid approach using DCA-based VMAT
optimization with a user defined MLC aperture controller. This approach used a DCA base
dose calculation and then slightly optimizes the treatment plan to further improve plan
quality, reduce intermediate dose spill and increase delivery accuracy.30 With this method,
Eclipse users can control the MLC field aperture shape and create a 3D dose distribution
using DCA planning before VMAT optimization. For utilization of DCA-based VMAT
planning, commissioning and validation of photon optimizer (PO)-MLC algorithm in
Eclipse TPS is required. Although, a few investigators have studied the clinical use of POMLC algorithm for VMAT lung SBRT plan optimization, the usefulness of DCA-based
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VMAT planning in the treatment of multiple brain metastases has not yet been reported.3032

Most recently, several researchers have performed comparison studies of singleisocenter VMAT plans with all other modes of SRS treatment to multiple brain metastases.
SIMT VMAT plans have similar conformity and whole brain V12Gy to that of GK SRS
with significantly reduced treatment times.33 Tomotherapy SRS plans were less conformal
due to the coplanar beam arrangements with longer treatment planning and delivery times
compared to single isocenter VMAT plans.19 SIMT VMAT plans provided better
conformity and V12Gy with the sacrifice of dose fall-off compared to CyberKnife
radiosurgery.34 Multiple isocenter plans have a higher dose fall-off outside the target, but
have significantly longer treatment time compared to single isocenter VMAT plans, though
dose conformity showed to be comparable between the two plans.35 SIMT VMAT plans
have higher conformity and brain V12Gy with shorter beam on times compared to
BrainLab Element, but with a tradeoff of low dose spread and mean brain dose.36
Though single isocenter VMAT plans increase clinic efficiency and patient
tolerability there is a tradeoff when treating multiple targets simultaneously. Multiple small
brain lesions cannot be seen on a daily conebeam CT (CBCT) to insure proper alignment.
Instead, alignment is done bony landmarks, making true individual tumor-to-tumor
localization nearly impossible. As a result, treatment delivery inaccuracies could be caused
by residual patient setup errors. Studies have shown localization and delivery inaccuracies
when treating multiple brain metastases using single SIMT VMAT plan to best deliver safe
and accurate treatments for these complex patients.

8

1.4

Radiobiology of Stereotactic Radiosurgery
Based on current clinical data of SRS, large doses per fractions produce high rate

of tumor cells death.45 Traditionally, conventionally fractionation schemes were used to
achieve high sparing of normal tissues around the tumor. Dose escalation with SRS and
SBRT has increased with increasing technology of image guidance and advanced radiation
therapy techniques to achieve high doses in the tumor and high dose falloff to limit dose to
normal tissues outside of the target. Classic radiobiology is described through the 5 R’s:
repair of sublethal cellular damage, repopulation of cells after radiation, redistribution of
cells within the cell cycle, reoxygenation of surviving cells and radiosensitivy.46,47
Radiobiological response models have been generated to model cell survival and to
measure cell killing for specific doses and tumor types. The linear quadratic (LQ) model
describes cell kill by either single or double DNA strand breaks. This model has become
adopted in many clinics to determine changes in treatment regiments and dose per
fractionation.48 This model has been used for many clinical trials to best estimate the risk
to normal tissues and tumor response. It is inherent in this model that reoxygenation is
accounted for between each fraction. When considering single high doses, there is a lack
of reoxygenation that is not accounted for. It would then be assumed that high doses of
radiation would produce less tumor cell kill for the same normal tissue damage.50 This is
not evident through current clinical follow-up results.51-55 The LQ model must not be
properly predicting tumor cell kill for these high doses of radiation. This model clearly
overestimates the tumor control rates with SRS techniques. Normal tissue doses may be
less than projected, which would allow for larger doses than predicted to be used. The LQ
survival cell curve bends continuously downward with increases in radiation dose with
increased contribution of the quadratic component of the model.56 This could be further
9

explained through antitumor effects that are not predictable with classic radiobiology as
explained, specifically secondary cell kill effects.
There are three types of indirect cell killing to consider: strand breaks by free
radicals, cell signaling of antitumor immunologic rejection and devascularization.46 Tumor
cells have weak, disorganized, fragile vasculature, making them sensitive to high dose
radiation damage. For this reason, literature suggests that devascularization as the mode of
secondary cells death.46,57-58 Previous studies show that irradiation of tumors with doses
higher than 15 Gy per fraction cause major vascular damage accompanied by deterioration
of intratumor microenvironment resulting in secondary cell death.59-61 This is further seen
by the inverted “hockey-stick” phenomena of the cell survival curve.61 In this cell survival
curve, the beginning part of the curve represents the death of oxygenated cells. As radiation
dose increases, the curve is less steep representing the death of hypoxic cells. As the dose
is increased even further, above 15 Gy, cell death increases due to that of vascular damage.
This bending of the curve and increases in cell death at higher doses of radiation is known
as the “hockey-stick” phenomena.61 Further understanding the radiological response of
high dose per fraction SRS, specifically how it relates to patient set up errors while using
a SIMT VMAT, is imperative when determining the usefulness of this treatment technique.
There are many advantages of treating multiple brain metastases using single
isocenter VMAT plan as discussed above. The usefulness and limitations of single
isocenter methods are still in need of investigation. There are still many questions left
unanswered, for example, how do we know patients are accurately setup when using a
single-isocenter plan? Patients are setup to the daily cone beam CT where the lesions are
not clearly visible, therefore alignment is done by matching the skull-based bony anatomy.
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What is the result if they are slightly misaligned? How can misalignments be managed?
How does target coverage change as a function of set up errors and what is the
radiobiological tumor response due to secondary cell death? What are the clinically
acceptable limits for patient’s set up errors considering indirect cell kill? These questions
must be answered in order for guidance to be provided to the treating physicians and
physicists to use this treatment technique more effectively in academic and the community
centers.

1.5

Purpose of Dissertation
SIMT VMAT is an efficient treatment modality for multiple brain metastases

patients, but does not account for isocenter misalignment, degrading treatment delivery
accuracy. The purpose of this dissertation is to evaluate the clinical usefulness and
limitations of SIMT VMAT as a treatment option for stereotactic radiosurgery for
multiple brain metastases patients. The suggestions described in this dissertation will
provide guidelines and some patient setup correction strategies for treating physicians and
physicists for generating Linac-based SRS protocol for the fast, safe, accurate and effective
treatment delivery of multiple brain metastases with SIMT VMAT plans.

1.6

Clinical Innovations and Impact
Clinical Innovation #1: Quantification of patient setup uncertainty in all six

dimensions, including the affect misalignment has on normal tissue organs.
Chapter 2 evaluates the limitations of SIMT VMAT treatments of multiple brain
metastases in its current clinical practice by investigating the dosimetric effects of
rotational and translational patient setup uncertainties. Multiple small brain lesions are not
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visible on a daily CBCT scan, making alignment to lesions a difficult task. Instead,
registration must be done to bony landmarks, leaving room for patient setup uncertainty.
Literature shows that SIMT VMAT could deliver suboptimal stereotactic treatment to
multiple brain metastases. Sagawa et al. looked at CBCT registration information to
quantify 3-dimensional rotational setup uncertainty. They concluded that significant under
dosing was evident due to the rotational setup errors.43 This work along with others
exclusively evaluates the detriment of rotational errors in this setting.35-45While treating
multiple brain lesions simultaneously, patient setup uncertainty is likely largely due to
contributions of translational errors as well. This means that single isocenter VMAT SRS
is an efficient treatment modality; however, due to small residual setup errors, single
isocenter VMAT, in its current use, is not an accurate SRS treatment modality for multiple
brain metastases. This study expanded on the effects of patient setup uncertainty when
treating with SIMT VMAT by quantifying loss of target coverage due to clinically
observable rotational and translational errors along with potential collateral damage to
adjacent normal tissues organs. We hypothesized that there would be a geometric
relationship between isocenter to tumor distance, tumor size and loss of target
coverage with potentially increased dose to surrounding critical structures. To explore
the hypothesis, small residual setup errors in all 6 DOF was induced and the effect on target
coverage was evaluated along with the change in dose to critical structures.
Clinical innovation #2: Utilization of user defined aperture controller and DCAbased VMAT optimization to improve the plan quality, treatment delivery efficiency and
accuracy compared to standard SIMT VMAT plan.
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Chapter 3 describes and compares DCA-based VMAT and standard singleisocenter VMAT approaches for SRS of multiple brain lesions. Small field dosimetry errors
are prevalent when using small beamlets in the delivery of highly modulated single
isocenter VMAT. These errors are due to the high modulation of MLC, creating beamlets
to treat multiple lesions simultaneously.62 These small field dosimetry errors must be
considered when using traditional single isocenter VMAT. Huang et al. first introduced the
use of single isocenter DCA (SIDCA) for the treatment of multiple brain lesions. This
reduced total number of monitor units for single isocenter VMAT plans, reducing the
treatment time, and therefore improving treatment efficiency and compliance.27 Traditional
VMAT approaches use flattening filter free (FFF) beams to allow for higher dose rates,
reduced lateral beam hardening and to reduce leakage and out of field dose from lateral
scatter and electron contamination.63-65 However, DCA-based approaches cannot utilize
FFF beams due to their non-uniform dose profile.66-67 With the development of the aperture
controller feature of the photon optimizer (PO)-MLC algorithm in the Eclipse TPS, a
hybrid of the two methods became possible with the development of DCA-based VMAT
approach.30,68 A 3D-DCA base dose is calculated before VMAT optimization. This has
been investigated for single dose of lung SBRT plans for improved plan quality and
treatment delivery efficiency and accuracy, but the usefulness of this approach in terms of
brain metastases is first reported in this thesis.30 It was hypothesized that utilizing that
DCA-based VMAT planning reduces MLC modulation through the multiple targets
and improve the plan quality, treatment delivery efficiency and accuracy compared
to traditional SIMT VMAT plans. To explore this hypothesis, a comparison study
between a novel DCA-based VMAT and traditional single isocenter VMAT plans was
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performed. This study sparks potential for incorporating DCA-based VMAT optimization
in single isocenter methods, similar to HyperArc VMAT, and warrants future investigation.
Clinical innovation #3: Creation of a novel risk adapted SIMT VMAT planning
approach for multiple brain metastases to minimize spatial setup uncertainties.
Chapter 4 introduces a novel correction strategy for patient setup errors using a
risk adapted planning approach where variable doses are prescribed based on distance to
isocenter, tumor size and proximity of the dose limiting organs at risk (OAR). It was
described in Chapter 2, that single isocenter VMAT treatments are prone to patient
rotational and translational positioning errors, generating large dosimetry disparity.35-45 Dr.
Ezzell from University of Minnesota analyzed the spatial accuracy of single isocenter
treatments using image guidance and concluded that spatial accuracy degrades at large
distances from the isocenter.42 Most current correction strategies, including suggestions by
Dr. Ezzell, involve adding an additional margin around the target. 37-45 Though this should
increase the delivery accuracy of these plans, this comes at high risk of high doses to the
normal brain tissue as well. To address this issue, this chapter introduces a new correction
strategy using variable prescriptions to multiple brain lesions. We hypothesized that by
escalating the prescription dose to 24 Gy, the loss of target coverage to small lesions
away from isocenter could be alleviated without adding additional margin around the
target(s). Similarly, prescribing 18 Gy to large tumors located near dose limiting OAR
would alleviate risk in a palliative setting. A plan comparison study was done between this
risk adapted planning approach and original DCA-VMAT style plans. With this method,
lesions at a large distance from isocenter can be managed while maintaining similar plan
quality with lower dose to OAR including normal brain tissue. This proposed solution
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would allow for SIMT VMAT to be both an efficient and accurate treatment modality for
patients with multiple brain metastases.
Clinical innovation #4: Creation of a novel dual isocenter VMAT SRS planning
approach for the management of multiple brain metastases that improves the plan quality
and minimize patient setup uncertainties.
Chapter 5 introduces a novel dual isocenter VMAT technique to alleviate the
dosimetric discrepancies of single isocenter VMAT for the management of multiple brain
metastases, as quantified in Chapter 2.35-45 Many researchers have made efforts to mitigate
this uncertainty, mostly through the use of added margins.44,69 In addition to the dosimetric
discrepancies due to patient rotational and translational errors, there is also an issue of
island blocking. This is when more than one lesion shares the same MLC pair. This creates
gaps between the lesions, allowing for low and intermediate dose spill, increasing the dose
to the normal brain and adjacent OAR. Treatment techniques, like HyperArc VMAT,
attempt to mitigate this issue using collimator optimization to each arc based on tumor
shape and configuration. Ohira et al. dosimetrically compared a collimator optimized
HyperArc VMAT plan to a non-collimator optimized VMAT plan. They concluded that
the collimator optimization did reduce dose to normal brain.70 Other research made the
similar effort through optimization of beam geometry.71 Collimator optimization could
help improving the plan quality, but cannot fully alleviate the issue of island blocking,
especially with a large number of targets involved. To overcome the issue of dosimetric
uncertainty and island blocking, Prentou et al. first introduced a dual isocenter planning
technique. They used two isocenters to limit the distance from isocenter to decrease the
spatial uncertainty. Decreases in spatial uncertainty for patients with less than 4 lesions
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was apparent, though no conclusions were made on the effect of normal tissue doses.72 It
was necessary for this planning technique to be simplified with a defined delivery strategy
along with the investigation of the role of island blocking in terms of sparing normal tissue
structures. Therefore, we hypothesized by grouping lesions in halves based on brain
hemisphere location, MLC travel can be limited along with dose bridging due to
island blocking, sparing OAR and reducing brain dose while maintaining optimal
plan quality. A comparison study of the single isocenter VMAT and dual isocenter VMAT
plans was performed to investigate this hypothesis. With the a simplified dual isocenter
method, it was expected that complex patients with many brain metastases could be treated
with similar plan quality and more accurate treatment delivery accuracy while limiting dose
to normal tissue compared to a single isocenter VMAT delivery.
Clinical innovation #5: Quantification of the role of indirect cell death in
dosimetric errors due to patient setup uncertainty using radiobiology models in a SIMT
VMAT setting.
Chapter 6 quantifies the role of secondary cell death in the treatment of multiple
brain metastases with SIMT VMAT and defines the relationship it has with patient setup
uncertainty. Recent clinical outcome studies show high rates of local tumor control for
single isocenter VMAT treatments, even with the presence of setup uncertainty discussed
in Chapter 2.51-55 For example, Alongi et al did a follow up observation of 43 patients with
multiple brain metastases at 6 months (average) from their SRS treatment. They observed
60% of patients had complete or partial response to radiation and 40% with stable control.
Though overall survival was not reported, positive local control rates are apparent. This
can be explained though effects of indirect cell kill. Specifically, doses higher than 15 Gy
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per fraction cause major vascular damage in the tumor accompanied by deterioration of
intratumor microenvironment resulting in secondary cell death.56-61We hypothesized that
in addition to direct cell kill, the effect of indirect cell kill could be playing a major
role in SRS treatments, resulting in positive local control rates. This biological
modeling was used to find a clinical threshold of patient setup errors to be maintained to
achieve tumor coverage for indirect cell killing to occur along with effects on normal brain
toxicity. By understanding the radiobiological concepts of secondary cell death on single
isocenter multi-lesion SRS treatments, physicians could have the opportunity to better
decide on the effectiveness of this treatment modality for multiple brain metastases.
Finally, Chapter 7 discusses the summaries and conclusions of each chapter,
limitations of this study and future research directions to utilize the innovative methods
and tools created in this study in the management of complex patients with multiple brain
metastases.

.
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CHAPTER 2. SINGLE ISOCENTER VMAT RADIOSURGERY FOR MULTIPLE BRAIN
METASTASES: POTENTIAL LOSS OF TARGET COVERAGE DUE TO ISOCENTER
MISALIGNMENT

To fully understand the usability of SIMT VMAT SRS in the treatment of multiple
brain lesions, we must first be able to understand its limitations. Patient positioning errors
are possible when treating with a single isocenter. It was necessary to quantify the effect
these patient setup errors had on tumor coverage, dose to critical structures and plan
quality. The results of this chapter exemplified the risk of treating multiple brain lesions
with a single isocenter, calling for methods of improvement. The following chapter has
been adopted from a published manuscript: Palmiero A, Critchfield L, St. Clair W, Randall
M and Pokhrel D. “Single-Isocenter VMAT Radiosurgery for Multiple Brain Metastases:
Potential Loss of Target(s) Coverage due to Isocenter Misalignment.” Cureus, 2020.
12(10):e11267.
Abstract
Purpose: A single-isocenter volumetric modulated arc therapy (VMAT) treatment to
multiple brain metastatic patients is an efficient stereotactic radiosurgery (SRS) option.
However, current clinical practice of single-isocenter SRS does not account for patient
setup uncertainty, which degrades treatment delivery accuracy. This study quantifies the
loss of target coverage and potential collateral dose to normal tissue due to clinically
observable isocenter misalignment.
Methods and Materials: Nine patients with 61 total tumors (2-16 tumors/patient) who
underwent Gamma Knife SRS were replanned in Eclipse using 10MV-FFF bream (2400
MU/min), using a single-isocenter VMAT plan, similar to HyperArc VMAT plan.
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Isocenter was placed in the geometric center of the tumors. The prescription was 20 Gy to
each tumor. Average gross tumor volume (GTV) and planning target volume (PTV) were
1.1 cc (0.02–11.5 cc) and 1.9 cc (0.11–18.8 cc), respectively, derived from MRI images.
Average isocenter to tumor distance was 5.5 cm (1.6–10.1 cm). Six-degrees of freedom
(6DoF) random and systematic residual set up errors within [±2 mm, ±2o] were generated
using an in-house script in Eclipse based on our pre-treatment daily conebeam CT imaging
shifts and recomputed for the simulated VMAT plan. Relative loss of target coverage as a
function of tumor size and distance to isocenter were evaluated as well as collateral dose
to organs-at risk (OAR).
Results: Average beam-on time was less than 6 minutes. However, loss of target coverage
for clinically observable setup errors were, on average, 7.9% (up to 73.1%) for the GTV (p
< 0.001) and 21.5% for the PTV (up to 93.7%) (p < 0.001). Correlation was found for both
random and systematic residual setup errors with tumor sizes; there was a greater loss of
target coverage for small tumors. Due to isocenter misalignment, OAR doses fluctuated
and potentially receive higher doses than the original plan.
Conclusion: A single-isocenter VMAT SRS treatment (similar to HyperArc VMAT) to
multiple brain metastases was fast with < 6 min of beam-on time. However, due to small
residual set up errors, single-isocenter VMAT, in its current use, is not an accurate SRS
treatment modality for multiple brain metastases. Loss of target coverage was statistically
significant, especially for smaller lesions, and may not be clinically acceptable if left
uncorrected. Further investigation of correction strategies is underway.
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2.1

Introduction
Multiple brain metastases are common among cancer patients. Twenty to fifty

percent of cancer patients develop brain metastases with the most common primary
malignancies being lung cancer, breast cancer, and melanoma.1 Historically, this was
treated with whole brain radiotherapy (WBRT), which resulted in normal tissue toxicities
such as memory loss, hair loss, pituitary dysfunction and diminished hearing, and positive
treatment outcomes were not achieved (with 100% failure at one year).2 More recently,
stereotactic radiosurgery (SRS) has gained popularity due to its high precision and
accuracy in a single treatment, providing good tumor local control rates and sparing critical
organs.3,4 For instance, a randomized trial from the MD Anderson Cancer Center on SRS
of multiple brain metastases patients with or without WBRT demonstrated inferior
neurocognitive results in the cohort who had received WBRT in addition to SRS.3 Of the
stereotactic treatment modalities for treating multiple metastases, Gamma Knife (GK)
radiosurgery is a gold standard.5 However, GK patients face many challenges such as
incredibly long treatment times, painful headframe placement, inability to affix the
headframe to craniotomy sites, and difficultly arranging anesthesia time for claustrophobic
patients. Though alternative treatment modalities such as robotic CyberKnife and ringmounted accelerators are available, long treatment times and inferior plan quality can be
problematic.6
Linac-based SRS treatments is an option to provide frameless SRS to brain
metastatic patients. This began through multiple isocenter dynamic conformal arcs (DCA)
or VMAT-based treatment planning where each target was planned and treated
individually. Isocenters were placed at the center of each tumor and setup and imaged
20

individually, allowing for corrections of residual setup errors around each isocenter.
Traditional Linac-based SRS treatments can impede clinic workflow due to individual
patient setup and conebeam CT (CBCT) imaging of each isocenter and long treatment
times. A new treatment planning and delivery approach is to treat multiple lesions
simultaneously using a single-isocenter VMAT plan, allowing for increased clinic efficacy
and tolerability.7 Varian recently introduced a Truebeam Linac-based (or superior) singleisocenter VMAT platform known as HyperArc as a module in the Eclipse treatment
planning system (TPS, Varian Medical Systems, Version 15.6) to mitigate all of these
challenges mentioned above.6,8,9 HyperArc (HA) VMAT can rapidly deliver treatment to
multiple brain metastates and improve patient compliance and comfort.
However, there is a tradeoff when treating multiple targets simultaneously using a
single-isocenter VMAT plan, similar to HyperArc plan. First, small multiple brain
metastases cannot be seen on a daily single CBCT to ensure proper target alignment.
Instead, alignment must be made by rigid registration to bony anatomy. As a result,
treatment delivery inaccuracies that could come with residual patient setup errors could
increase. Second, lining up multiple brain tumors accurately using a single daily CBCT is
almost impossible. Studies have shown localization and treatment delivery inaccuracy
when treating multiple brain lesions using HyperArc VMAT.9-11 For example, Sagawa et
al. used CBCT registration information to induce a 3-dimensional rotational setup
uncertainty.9 They concluded that non-negligible under dosing to the PTV was due to
residual rotational set up errors. Although they successfully explain the presence and
dosimetric effects of rotational set up uncertainties, their work excludes consideration of
small translational effects in addition to the rotational errors. This study is innovative in
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the sense that it includes setup uncertainties in all 6DOF to further quantify the treatment
delivery inaccuracy of HyperArc style single-isocenter VMAT plan. This work was
performed in a clinically representative manner for the commissioning of single-isocenter
VMAT treatments. The Eclipse TPS was used entirely and isocenter misalignments were
randomly induced errors to mimic representative patient positioning uncertainties for SRS
treatments using an in-house script. Thus, the main purpose of this study is to fully quantify
the dosimetric effects resulting from clinically attainable residual patient set up errors in
all 6-directions for single-isocenter/multi-lesions technique. Relative loss of target
coverage as a function of tumor size and distance from isocenter was investigated.
Additionally, collateral dose to the adjacent organs-at-risk (OAR) was evaluated.

2.2
2.2.1

Materials and Methods
Patient images and contouring
After obtaining an Institutional Review Board (IRB) approval, nine patients with

multiple brain metastases (all lung primary) were included in this retrospective study.
These patients were previously treated with frame-based GK radiosurgery using highresolution double contrast MPRAGE MRI imaging (Siemens MAGNETOM, 1.5T MRI
System, Ferndale, MI). The MRI images were 512×512 pixels and 1 mm slice thickness
with no gap between the slices. These DICOM MRI datasets were transferred from the GK
planning station into Varian Eclipse TPS for contouring and planning. The target volumes
were delineated by an experienced radiation oncologist on the MRI and the gross tumor
volumes (GTVs) were defined by the visible tumor in the MRI images. The planning target
volumes (PTVs) were created using a uniform 1.0 mm margin around each GTV. There
were 2-16 lesions per patient with total 61 lesions. The tumor characteristics are
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summarized in Table 1. The OAR’s were delineated including: optics apparatus (both
optics nerves plus chiasm), brainstem, eyes and lenses, normal brain (brain minus PTVs)
and hippocampi (left and right hippocampus). The hippocampi contours were done
following RTOG-0933 atlas.12 Since no planning CT images were available for these
patients, for treatment planning purposes, a homogenous medium was assigned to the body
contour in Eclipse TPS with a CT value of 0. Distance to isocenter was calculated by
finding the coordinates of the PTV geometric center and determining the distance from the
isocenter coordinates for each lesion.
Table 2.1 Main tumor characteristics of the patients included in this study.
Parameters
Mean ± STD (range)
Total tumors (n = 9 patients)

61 (2–16/patient)

GTV (cc)

1.06 ± 1.85 (0.03–11.5)

PTV (cc)

1.88 ± 2.86 (0.11–18.8)

Prescribed dose to each lesion

20 Gy in 1 fraction (70-80% isodose line)

Isocenter to tumors distance (cm)

5.50 ± 1.80 (1.58–10.15)

Tumor location (bi-lateral brain)

(all patients)

Normal brain (cc) = Whole brain minus

1517 ± 198 (1213–1705)

PTVs
2.2.2

Original VMAT plans
HyperArc (HA) style single-isocenter VMAT SRS plans were generated in the

Eclipse TPS for the Truebeam Linac (Varian Medical Systems, Palo Alto, CA) with
standard millennium MLCs and 10MV-FFF beam (maximum achievable dose rate of 2400
MU/min). The plans mimicked HyperArc VMAT geometry with the use of 4-5
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noncoplanar arc arrangements, replicating gantry rotation and couch kicks. Isocenter was
placed at the approximate geometric center of all the tumors. The collimator angles were
chosen manually to minimize island blocking and dose outside of the target. Dose was 20
Gy to each lesion prescribed to the 70-80% isodose line. The plans were optimized so that
95% of each PTV received at least 100% of the prescription dose with the hotspot at the
center of the GTV. The dose was calculated with Anisotropic Analytic Algorithm (AAA)
(Eclipse, version 15.5) with 1.25 mm calculation grid size. Inverse optimization was
performed with the photon optimizer (PO) MLC algorithm with individual dose steering
ring structures to each target. Jaw tracking and normal tissue objective (NTO) was used to
control the dose fall-off outside of each target for better dose conformity and to spare
adjacent OAR. Planning objectives followed RTOG 0933 guidelines for hippocampal
sparing that were converted to SRS dose constraints using biological effective dose,
allowing maximal dose to hippocampus to be < 6.5 Gy.12,13 Other OAR followed
QUANTEC guidelines for single fraction treatments such as maximal dose to optic
apparatus < 8.0 Gy.14 Average beam on time for original VMAT plans was recorded 5.20
± 0.97 min (range, 3.01–6.02 min). Beam-on time was calculated by taking the total
monitor units divided by the maximum dose rate setting of 2400 MU/min for 10 MV-FFF
beam.
2.2.3

Simulated VMAT plans
A novel in-house method was developed to simulate clinically realistic residual

setup errors by inducing uncertainties within a range of ±2 mm and ±2° in all 6DoF. These
induced uncertainties were chosen randomly to mimic prospective daily CBCT setup errors
obtained at the machine in a clinically realistic setting based on previous SRS patient’s
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data. The residual translational errors were defined for isocenter displacements. The
rotational errors were defined for patient rotations relative to the isocenter around the rightleft (pitch), anterior-posterior (yaw) and superior-inferior (roll) directions. After the singleisocenter VMAT plans were generated, the patient MRI images were duplicated and coregistered to the original MRI. The image registration DICOM file was exported from the
Eclipse TPS and imported into an in-house MATLab script that generated random
rotational (Δα, Δβ, Δγ) and translational (Δx, Δy, Δz) errors within [±2°, ±2 mm] in each
direction. These matrices were then applied to the reference frame, and the output was a
new image registration file with a simulated shift in 6DoF. The image registration DICOM
file was imported back into the Eclipse TPS with the new transformation matrix applied to
the registered MRI images. The single-isocenter VMAT plan was then overlaid on to the
new registered image and dose was re-calculated with the only difference in the plans being
the shift in the isocenter. For better statistics, each patient’s original plan was simulated 10
times and all the output data averaged. A visual scripting tool (Varian Medical Systems,
Palo Alto, CA) (see Appendix 2) was used to export relevant dosimetric parameters for
plan comparison. This process provides all dosimetric parameters including OAR doses
using the same dose calculation algorithm as the original plan.
This same method was used to systematically induce setup uncertainties. Instead of
randomly generating the translational and rotational matrices, they were set to [±0.5 mm,
±0.5°]; [±1 mm, ±1°] and [±2 mm, ±2°] in each direction, systematically. With these
systematic errors, the image registration was then repeated and the original single-isocenter
VMAT plan was overlaid on to the new image set for comparison as described above.
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2.2.4

Plan comparison and data analysis
The simulated VMAT plans with isocenter misalignment were compared to the

original single-isocenter VMAT plans. The visual scripting tool (see Appendix 2) exported
dose volume histogram (DVH) parameters used to evaluate the plan quality. The minimum,
mean and maximum doses to GTV were evaluated between the plans. The PTV coverage
was assessed by a comparison with original PTV D95% coverage. The OAR’s were
evaluated using maximal doses to hippocampi, brainstem, and optics apparatus. Dose to
the normal brain was assessed using mean brain dose (MBD), V12 and V16.15 For each
target, heterogeneity index (HI), Paddick conformation number (CN), and under-treatment
ratio (UR) were evaluated.16 The HI is the ratio between the maximum dose in the target
target (DMax ) and the prescription isodose (𝐷𝐷𝑅𝑅𝑅𝑅 ). A HI value of less than 2.0 meets protocol
guidelines. The Paddick CN is defined as the ratio of the target volume covered by the
prescription isodose (TV_RX) to the product of the target volume (TV) and the total
volume covered by the prescription isodose (VRX). This parameter accounts for the
position of the prescription isodose relative to the target volume. Additionally, the Paddick
CN was evaluated via the under-treatment ratio (UR), where a value of 1.0 represents a
fully covered or overly treated lesion and less than 1.0 represents an undertreated lesion.
Loss of target coverage for both randomly generated and systematically induced setup
uncertainties were evaluated as a function of target volume and distance to isocenter. A
paired two‐tail student’s t‐test (Microsoft Excel, Microsoft Corp., Redmond, WA) was
used to compare the data for the original VMAT vs simulated VMAT plans for all
dosimetric parameters of target coverage and to the OAR. A value of p < 0.05 was used as
a cutoff for statistically significant.
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2.3

Results

2.3.1

Simulated random errors
The analysis of target coverage for all nine patients (61 lesions) randomly simulated

10 times each is shown in Table 2. Simulated VMAT plans showed an average loss of PTV
coverage of 21.5 ± 13.6% (range, 0.4–94.7%) compared to the original VMAT plans. After
applying clinically observable random transformations, major loss in PTV coverage, CN,
UR and HI were observed. The severe loss in the average values of CN (p < 0.001) and UR
(p < 0.001) for the simulated VMAT plans suggests that the prescription isodose volume
did not cover the PTV as planned originally. The minimum and mean doses to GTVs were
decreased by an average of 3.6 Gy and 1.5 Gy, signifying underdosing of the GTVs.
Table 2.2 Analysis of the loss of target coverage for each plan
Target (s) Parameter
Original VMAT
Simulated VMAT

GTVs

Max dose (Gy)

plans

plans

25.4 ± 0.5 (24.5–26.1)

25.3 ± 0.51 (24.3–

p-value

p = 0.385

26.1)
Min dose (Gy)

21.9 ± 0.65 (20.8–

18.3 ± 2.2 (14.3–

23.3)

21.3)

24.0 ± 0.47 (23.2–

22.6 ± 1.4 (19.8–

24.8)

24.6)

% Volume

98.7 ± 1.4 (95.0–

77.2 ± 13.7 (5.0 –

covered by Rx

100.0)

99.7)

0.70 ± 0.11 (0.35–

0.43 ± 0.18 (0.04–

0.91)

0.89)

Mean dose (Gy)

PTVs

p < 0.001

p < 0.001

p < 0.001

dose (%)
CN
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p < 0.001

Table 2.2 (Continued)
UR

HI

0.95 ± 0.15 (0.13–

0.75 ± 0.16 (0.13–

0.913)

1.0)

1.3 ± 0.03 (1.1–1.3)

1.2 ± 0.04 (1.0–1.3)

p < 0.001

p = 0.04

Figure 2.1 shows an axial, coronal, and sagittal view of the original and simulated
VMAT plans for an example patient with 16 tumors (not all tumors are seen). With induced
random setup uncertainties within [-2.0, +2.0] mm and [-2.0, -2.0] degrees in all 6DOF,
major loss of both GTV and PTV coverage was observed. In the simulated VMAT plan,
loss of target coverage was evident due to the visible difference in overlap of the PTV
(orange) and the prescription isodose lines (green).
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Figure 2.1 Example of loss of coverage seen in patient with 16 tumors.
An axial, coronal and sagittal view of an example case with 16 tumors: Original VMAT
plan (upper panel) and simulated VMAT plan (lower panel) with randomly induced
residual set up errors of ±2.0 mm and ±2.0o in each direction. The prescription isodose line
(green) conformed to each lesion as in original plan. Loss of target coverage is seen in the
simulated VMAT plan (see lower panel) and shifted the higher isodose line closer to the
hippocampus.

This is further illustrated in the DVH (see Figure 2.2) with the original VMAT plan
(triangle) and simulated VMAT plan (square). The blue arrow shows the original intended
coverage for all targets (> 95% of PTVs receiving 20 Gy dose). Loss of PTV (orange)
coverages were observed up to 45% and loss of GTV (red) coverages of up to 25% in some
lesions. OAR doses fluctuated depending on the random uncertainty induced to the
simulated VMAT plans, and in some cases resulting in substantial increases to OAR doses.
Figures 2.1 and 2.2 demonstrate the example case of an increased dose to the hippocampus
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(pink color). In the original plan, the maximal dose to hippocampi was kept below 6.3 Gy.13
With induced random errors in the simulated VMAT plan, maximal dose to hippocampi
was 8.1 Gy, exceeding the protocol requirement of 6.5 Gy. This was visible in the sagittal
image of the Figure 2.1 above where the 50% isodose line (10 Gy) was perturbed towards
the hippocampus (pink contour) and also shown in DVH (see figure 2.2).

Figure 2.2 Comparison of DVH for iriginal VMAT plan (triangle) and simulated
VMAT plan (square)
Comparison of dose volume histogram (DVH) for the original VMAT plan (triangle) and
the simulated VMAT plan (square) with randomly induced residual set up error in 6DoF.
Vertical blue arrow shows the original planned coverage to all PTV. Brainstem (blue) and
normal brain (green) are shown. Due to small, clinically observable residual patient setup
errors, unacceptable loss of target coverage was observed along with increased dose to
hippocampi (pink).
An analysis of loss of coverage for all nine patients with setup uncertainty is
displayed in Figure 2.3. The probability distribution function of coverage loss due to GTVs
and the PTVs is shown. The number of occurrences of a particular coverage loss was
binned in the histograms for all 10 iterations of the simulation for all nine patients (61
original targets, total 610 simulated targets). The red line represents the distributions
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correlating to the histogram with relative target coverage losses for GTVs and PTVs with
the average values of 7.9 ± 11.1% and 21.5 ± 13.6%, respectively. This means for a typical
single-isocenter VMAT plan, predictively, a loss of coverage of this magnitude would
potentially exist during multiple brain metastases SRS treatment.

Figure 2.3 Probability distribution functions demonstrating the loss of coverage for
all 9 patients.
Probability distribution functions demonstrating the loss of coverage for both the GTVs
(left) and PTVs (right) of all nine patients (61 tumors), randomly repeated each patient over
10 times (610 iterations). Residual set up errors between [± 2.0 mm, ± 2.0o] were applied
in all 6DoF to replicate the day-to-day clinically representative residual set up errors. Due
to these small set up errors, clinically unacceptable loss of target coverage was observed,
which projects the magnitude of loss that would be seen in a typical single-isocenter
VMAT treatment.
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Figure 2.4 Scatter plots of loss of target coverage as a function of tumor volume and
distance to isocenter.
Scatter plots of the relative dose errors of target coverage due to random residual set up
errors as a function of tumor volume and distance to isocenter for both GTVs (upper panel)
and PTVs (lower panel) were shown. Greater loss of target coverage for smaller tumor
sizes was correlated for both GTVs and PTVs. However, no obvious trends were seen when
comparing loss of coverage and distance from isocenter while simulating all 6DoF residual
set up errors.
The loss of target coverage due to random residual set up errors in 6DoF as a
function of tumor size and distance to isocenter for the both GTVs and PTVs are shown in
Figure 2.4. A clear trend was evident that with a smaller GTV and PTV, there was increased
loss of target coverage (see left panel). However, there was no correlation between loss of
coverage and distance to isocenter (right panel). This could be due to randomly generated
clinically realistic translational error of ±2 mm (in each direction) dominating small but
clinically observed rotational error of ±2° (in each direction). The variation in patient
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parameters such as tumor number, size and distance to isocenter could make such a trend
difficult to detect.
Regarding normal brain dose, no statistically significant difference was observed
for MBD (p = 0.41), V12 (p = 0.97), V16 (p = 0.79). However, in some cases the maximal
difference was up to 1.0 Gy, 5.2 cc and 5.9 cc. In the Linac-based SRS treatments, Blonigen
et al. reported that normal brain V8 to V16 were the best predictors for radio-necrosis.
Therefore, we caution that in some cases, maximal difference in V16 up to 5.9 cc could be
detrimental to the normal brain.17 Maximal dose increase of brainstem, optic apparatus and
hippocampi were < 2.0 Gy, < 0.4 Gy, and < 2.7 Gy, respectively.
2.3.2

Simulated systematic errors
To evaluate worst-case scenarios, we simulated single-isocenter VMAT plans with

systematically assigned rotational and translational errors in all six-directions. This was
performed by inducing systematic ±0.5 mm, ±1 mm, and ±2 mm, and ±0.5o, ±1o, and ±2o
errors in all 6DoF; results are shown in Figure 2.5. These simulations compared the results
of relative loss of PTV coverage for all 61 tumors. Loss of target coverage was a function
of both the magnitude of induced uncertainty and tumor volume. The loss of target
coverage due to systematic residual set up errors for 0.5 mm, 1 mm, and 2 mm, and 0.5o,
1o, and 2o errors were 6.0 ± 3.1% (range, 0.5–15.6%), 18.2 ± 6.9% (range, 6.6–34.1%) and
42.9 ± 15.0% (range, 16.2–87.7%), respectively. Similar results were obtained for the
negative direction (see Figure 2.5).
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Figure 2.5 Loss of coverage as a function of PTV volume for systematic errors
Scatter plots of loss of target coverage as a function of PTV volume is shown for all 61
targets. All systematically induced errors were within [±2 mm, ±2o] in all 6DoF. There was
greater loss of target coverage for smaller tumors with the larger residual set up errors
(green).
2.4

Discussion
In this clinically representative simulation study, the dosimetric impact of clinically

observable 6DoF residual setup errors in HyperArc style single-isocenter VMAT plans in
the treatment of multiple brain metastases have been evaluated. Clinically unacceptable
loss of target coverage for smaller tumors was observed when simulating residual isocenter
misalignments. After applying clinically achievable random translational errors of ±2 mm
and rotational errors of ±2° in each direction, the dramatic loss of the PTV coverage was
observed with an average relative dose error of 21.5 ± 13.6% (up to 94.7% in some lesions)
(p < 0.001). This suggests that this technique could have major limitations treating multiple
brain lesions synchronously. Minimum dose to GTVs was lower by almost 4.0 Gy, on
average, suggesting potential underdosing of small tumors.
Due to faster treatment delivery, Linac-based VMAT SRS is becoming increasingly
utilized, specifically using single-isocenter SRS.18 Average beam on time was less 6
minutes. Varian developed a novel technology to automate this process using single34

isocenter HyperArc VMAT for multiple lesions brain SRS.19 Localization of each lesion is
of utmost importance when escalating dose to a small region. This is a difficult task,
especially when treating multiple brain metastases simultaneously via a single-isocenter
VMAT plan, including HyperArc VMAT. Patients are setup using a daily single CBCT to
align bony anatomy; targets are not visible on daily CBCT, so targets are not localized
individually. Small patient misalignments result in clinically significant loss of coverage
and could deliver a very high dose adjacent to the tumor. This finding is of utmost
importance because the HyperArc style single-isocenter VMAT could potentially deliver
dosimetrically unacceptable treatments to patients through a near or complete geometric
miss of the small brain lesions and increase damage to the adjacent critical structures.
Major loss of dose conformity, lower GTV dose, higher relative dose errors for smaller
lesions, and potentially higher doses to OAR’s including hippocampi and normal brain V12
and V16 have been demonstrated.
Other researchers have studied the loss of target coverage due to residual patient
setup errors.9,20-25 Sagawa et al. reported that due to rotational set up errors there was nonnegligible underdosing of PTV coverage and significant increase of normal brain V10 to
V16 for multiple brain metastases patients with HA-VMAT plans. Uncertainties were
simulated using a 3rd party software (MIM Maestro, MIM software Inc., USA) that could
add additional source dosimetric errors.11 Rotational set up errors were up to ± 3° in each
direction. Roper et al. systematically induced rotational errors of 0.5°, 1.0°, and 2.0° using
Velocity AI (Velocity Medical, Atlanta GA) registration software.24 They demonstrated a
correlation between diminishing PTV coverage and distance from isocenter; however, their
study was performed only using systematic rotational setup errors in single‐isocentric
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VMAT plans consisting of only two lesions. Their results showed that PTVD95% values
worsened up to 60% of the prescribed dose in systematic rotations of 2° about all three
axes. However, they did not include potential translational pretreatment set up errors and
did not report the impact on OAR doses. In contrast, this study included all 6DoF residual
set up errors for patients with multiple brain lesions (up to 16) and reported changes in
OAR’s.
This investigative approach is more consistent with clinical realities by including
all 6DoF residual patient set up errors and resulted in an even greater loss of target coverage
than what other studies have shown. An innovative aspect of this study is that it uses
computer generated random uncertainties in all rotational and translational directions (in
Eclipse) to apply to isocenter to simulate patient setup errors. This successfully simulates
the types of errors encountered in a clinical setting without using a third-party software,
which avoids adding other sources of dosimetric discrepancy. Another novelty in this study
is the diversity of patients. Most similar studies used patients with few tumors whereas
patients in this study had up to 16 tumors (average 7) and a total of 61 lesions. Unlike other
studies, the simulations and treatment planning were all done within the Eclipse TPS,
minimizing other sources of error and making it more clinically representative. This tool
can be used for both intracranial as well as extracranial multi-lesions and single-lesion
stereotactic treatments settings.
There are some limitations of this study. First, due to the lack of HyperArc planning
license, HyperArc style single-isocenter VMAT plans were simulated. Although, the arc
geometry of HyperArc was kept the same, collimator optimizations were done manually to
minimize the out of field dose on a per-patient basis. Second, this is a retrospective study
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of previously treated frame-based GK radiosurgery patients using high-resolution MRI
imaging. Therefore, we did not have an appropriate planning CT imaging for heterogeneity
corrections. For this simulation study, homogenous dose to the brain was calculated
assigning a CT value equal to water. However, in a Monte Carlo study by Pokhrel et al.
with fractionated-SRS treatments of cavernous sinus tumors, it was demonstrated that dose
discrepancy is less than 2% in the brain with pencil-beam algorithm.26 Although, a
homogenous medium is used in routine GK radiosurgery treatments, we acknowledge that
heterogeneity corrections will introduce most likely a small dosimetric errors in the brain
compared to these large discrepancies due to residual set up errors. In the future, planning
CT images will be used for actual patient treatment via single-isocenter VMAT, coregistering MRI for tumors and OAR delineation. Due to the proximity of multiple brain
lesions and island blocking problems (two or more lesions sharing the same MLC pairs),
the spread of 50% isodose lines created higher dose bridging in between/among the tumors.
This created a major difficulty in calculating gradient indices for each lesion (results not
shown here). Another limitation to the study is using standard MLCs of 5 mm width.
Single-isocenter VMAT for multiple brain lesions is primarily limited to linear accelerators
utilizing 2.5 mm high-definition MLCs. However, a recent study from Duke demonstrated
that for radiosurgery of multiple brain metastases using a single-isocenter VMAT plan, 5
mm MLCs can produce similar target conformity with slightly increased 30-50% isodose
spillage, but this can be minimized by adding one or two more VMAT arcs.27
In summary, a single-isocenter VMAT treatment similar to HyperArc VMAT for
multiple brain metastases can reduce treatment time significantly and improve treatment
tolerability and clinic workflow. However, due to small but clinically relevant residual set
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up errors an unacceptable loss of target coverage is observed. This could increase dose to
OAR including normal brain. It is therefore very important for any HyperArc style VMAT
users to quantify these dosimetric discrepancies and develop correction strategies to
minimize the dosimetric effects. Potential correction strategies are possible. First, institute
an asymmetric margin around the GTV as a function of target volume and distance to
isocenter. Second, assign risk-adapted prescriptions up to 24 Gy (rather than 20 Gy) to
small lesions away from the isocenter and no critical structures around the tumor. Third,
create dual-isocenter VMAT plans, rather than single-isocenter plan, for a large number of
multiple brain metastases as a function of distribution of the lesions in the brain, dividing
the brain into two equal volumes. Any of these correction strategies could potentially
compensate for the loss of target coverage and could be adopted on a patient-specific basis.

2.5

Conclusion
Rapid treatment of multiple brain lesions using a single-isocenter VMAT is

possible; however, small setup errors can result in large deviations from the planned target
coverage, specifically for the smaller targets. This loss of target coverage due to small
isocenter misalignment cannot be ignored for single-isocenter VMAT plan, similar to
HyperArc VMAT plan. In some cases, large increases of normal brain dose V12 and V16
and maximal dose to OAR including hippocampi could be harmful. Further investigation
of correction strategies is warranted.
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CHAPTER 3. A NOVEL DYNAMIC CONFORMAL ARC-BASED SINGLE ISOCENTER VMAT
PLANNING FOR RADIOSURGERY OF MULTIPLE BRAIN METASTASES

Upon the confirmation of risks target coverage loss due to patient positioning
uncertainty when treating with SIMT VMAT, improvements in plan quality was warranted.
A DCA base VMAT hybrid planning approach was developed to minimize small field
dosimetry errors and improve overall plan quality compared to traditional SIMT VMAT
methods. These results gave insight to alternative methods for the fast and more accurate
treatment of multiple brain metastases with single isocenter Linac-based stereotactic
radiosurgery. The following chapter has been adopted from a recently accepted article:
Pokhrel D, Palmiero A, Bernard M, and St Clair W. “A Novel Dynamic Conformal Arcsbased Single Isocenter VMAT Planning for Radiosurgery of Multiple Brain Metastases.”
Med Dosim, 2020; 1-6 (Article in Press) Elsevier.
Abstract
Purpose: Multiple small beamlets in the delivery of highly modulated single-isocenter
HyperArc VMAT plan can lead to dose delivery errors associated with small-field
dosimetry, which can be a major concern for stereotactic radiosurgery (SRS) for multiple
brain lesions. Herein, we describe and compare a clinically valuable dynamic conformal
arc (DCA)-based VMAT (DCA-VMAT) approach for SRS of multiple brain lesions using
flattening filter free (FFF) beams to minimize this effect.
Methods: Original single-isocenter HyperArc style VMAT and DCA-VMAT plans were
created on 7 patients with 2-8 brain lesions (total 35 lesions) for 10MV-FFF beam. 20Gy
was prescribed to each lesion. For identical planning criteria, DCA-VMAT utilizes usercontrolled field aperture shaper before VMAT optimization. Plans were evaluated for
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conformity and target coverage, low- and intermediate dose spillages to brain volume that
received more than 30% (V30%) and 50% (V50%) of prescription dose. Additionally,
mean brain dose (MBD), V8, V12 and maximal dose to other adjacent organs-at-risk
(OAR) including hippocampi were reported. Total monitor units (MU), beam modulation
factor (MF) and treatment delivery efficiency and accuracy were recorded.
Results: Comparing with original VMAT, DCA-VMAT plans provided similar tumor
dose, target coverage and conformity, yet tighter radiosurgical dose distribution with lower
dose to normal brain V30% (p = 0.009), V50% (p = 0.05) and other OAR. Lower total
number of monitor units and smaller beam modulation factor reduced beam on time by
2.82 min (p < 0.001), on average (maximum up to 3.8 min). Beam delivery accuracy was
improved by 8%, on average (p < 0.001) and maximum up to 13% in some cases for DCAVMAT plans.
Conclusions: This novel DCA-VMAT approach provided excellent plan quality, reduced
dose to normal brain and other OAR while significantly reducing beam-on time for
radiosurgery of multiple brain lesions –improving patient compliance and clinic workflow.
It also provided less MLC modulation through the targets –potentially minimizing small
field dosimetry errors as demonstrated by quality assurance results. Incorporating DCAbased VMAT optimization in HyperArc module for radiosurgery of multiple brain lesions
value future investigation.

3.1

Introduction
Traditional Linac-based stereotactic radiosurgery (SRS) treatment to multiple brain

lesions requires an individual plan to each lesion with a separate isocenter placed in the
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center of each lesion. Currently many clinics around the globe use this technique by using
circular arcs with stereotactic cone-mounted linac or multileaf collimators (MLC)-based
3D dynamic conformal arc (DCA), intensity modulated radiosurgery and volumetric
modulated arc radiosurgery plan placing the Linac isocenter at each target. 1, 2For multiple
brain lesions, this requires huge treatment planning effort, prolonged patient set up to each
isocenter and overall longer treatment time as well as patient collision issues with the conemounted linac heads. To overcome this difficulty, Huang et al. developed a single-isocenter
dynamic conformal arcs (SIDCA) based radiosurgery technique for multiple brain lesions
using high-definition MLC. 3 In a SIDCA plan, there is a single-isocentere position at the
geometric center of all the lesions, while each lesion is treated with DCA . This SIDCA
approach was later adopted by BrainLAB AG (Feldkirchen, Germany) system for multiple
brain lesions as Multiple Metastases Elements (MME). The main benefits of SIDCA
planning being: reduction of treatment planning and treatment delivery time due to singleisocenter setup, fewer conebeam CT scans, fewer treatment fields, and less number of total
monitor units (MU), improving treatment efficiency and patient compliance. However, this
approach could work well for traditional flattened beams but it may not be very suitable
with flattening filter free (FFF) beams due to their unflattened dose profiles. 4, 5Compared
to the traditional flattened beams, FFF beams have certain advantages for radiosurgery
treatment, including higher dose rates, reduced lateral beam hardening, and reduced
leakage and out-of-field dose due to less lateral scattering and electron contamination,
without increasing tissue toxicity and gaining whispered popularity in the clinic for single
and multiple lesion stereotactic treatments. 6-8
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Recent advances in technology have allowed for the use of volumetric modulated
arc therapy (VMAT) in the treatment of multiple brain lesions using a single-isocenter
technique with single or multiple arcs. 9-13 For instance, Clark et al from the University of
Alabama at Birmingham were the first to demonstrate the feasibility of using singleisocenter VMAT for multiple brain lesions.

9

To further improve the plan quality by

minimizing the inter-planners variability and to fully automate the treatment planning and
delivery, Varian recently introduced a Truebeam Linac-based (or superior) single-isocenter
VMAT platform known as HyperArc (Varian Medical Systems, Palo Alto, CA) as a
module in the Eclipse treatment planning system (TPS). This module is generating a global
clinical interest in the treatment of multiple brain lesions simultaneously.

14-17

This new

treatment planning and delivery module allows for treatment of multiple brain lesions
simultaneously using a single-isocenter VMAT plan, allowing for an increased clinic
efficiency and tolerability for the multiple brain metastatic patients. However, unlike
SIDCA plans, extremely modulated HyperArc VMAT plans that are highly susceptible to
delivery uncertainties due to small-field dosimetry errors.18 That is due to MLC modulation
of multiple beamlets through the multiple small targets simultaneously. To minimize MLC
modulation effects and further improve the plan quality Varian Eclipse TPS has recently
implemented a new multileaf collimator (MLC) optimization algorithm, called Photon
Optimizer (PO). 19PO offers a new MLC aperture shaper controller. With this new feature,
Eclipse users can control the field aperture shape and create a 3D dose distributions using
DCA before VMAT optimization. Although a few investigators have studied the clinical
use of PO-MLC algorithm for VMAT lung SBRT plan optimization, 20-22the dosimetric
effects and treatment delivery complexity of this planning approach with a FFF-beam in
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the treatment of multiple brain lesions using a HyperArc style VMAT plan has not yet been
reported.
Thus, as a part of our Linac-based stereotactic radiosurgery commissioning of
Eclipse TPS (Version 15.6), it is important to highlight the importance of investigating new
planning features to provide the highest quality plan and the most efficient and accurate
treatment delivery. When using a highly modulated single-isocenter VMAT plan for
multiple small brain lesions, the MLCs must travel a longer distance to provide adequate
coverage to each lesion simultaneously. Moreover, dose to radiosensitive organs including
nontarget normal brain is a major concern in treating multiple brain lesions synchronously
using a single-isocenter VMAT plan. 23-29Therefore, in this report we have retrospectively
evaluated this new feature on seven patients with multiple brain metastases for improving
plan quality and treatment delivery efficiency and accuracy. For comparison, the original
HyperArc style VMAT plans were re-optimized using a DCA-based VMAT (DCAVMAT) planning approach with identical beam geometry, dose calculation algorithm, grid
size, planning objectives and parameters. The DCA-VMAT plans utilized DCA-based dose
with the high strength of field-aperture shaper control priority before VMAT optimization–
therefore, less beam modulation through the multiple targets is expected. The original
VMAT plans and re-optimized DCA-VMAT plans were compared for target coverage and
conformity, low- and intermediate- dose-spillage to normal brain and dose to OAR.
Additionally, treatment delivery efficiency and accuracy were reported.
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3.2
3.2.1

Materials and methods
Patient population
Seven patients with a range of 2-8 brain metastases (all lung primary) were included

in this retrospective study approved by our institutional ethic committee. These patients
were previously treated through single fraction SRS in our institution using a highresolution double contrast MPRAGE MRI imaging (Siemens MAGNETOM, 1.5T MRI
System, Ferndale, MI) on GammaKnife. The MRI images were 512×512 pixels and 1 mm
slice thickness with no gap in between the slices. These DICOM MRI datasets were
transferred into Varian Eclipse TPS for targets and critical structures contouring. The target
volumes were delineated by an experienced radiation oncologist on the MRI and the gross
tumor volumes (GTVs) was defined by the visible tumor in the MRI images. The planning
target volumes (PTVs) were created using a uniform 1.0 mm margin around each GTV
using a departmental SRS protocol. There were 2-8 lesions per patient with a total of 35
lesions. The tumor characteristics are summarized in Table 1. The OAR were delineated
including: optics apparatus (both optics nerves plus chiasm), brainstem, eyes and lenses,
normal brain (brain minus PTVs) and hippocampi (left and right hippocampus). The
hippocampi contoured was done following RTOG-0933 atlas. 24 Distance to isocenter was
calculated by finding the coordinates of the PTV geometric center and determining the 3D
Euclidian distance from the isocenter coordinates for each lesion.
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Table 3.1 Tumor characteristics of the patients included in this study
Patient No. of
Average distance
Volume of each lesion (cc)
no.

lesions

Total

from isocenter

PTV

(cm)

(cc)

I

2

2.5

2.94, 4.37

7.37

II

3

5.8

1.82, 0.28, 0.65

2.76

III

4

6.4

18.79, 1.04, 1.90, 4.17

25.91

IV

5

8.9

12.05, 1.98, 5.00, 4.48, 1.04

24.54

V

6

5.5

3.56, 3.42, 1.49, 1.43, 1.13, 1.35

12.38

VI

7

5.1

3.88, 1.81, 1.40, 0.92, 0.73, 0.57, 0.85

10.16

VII

8

4.3

0.49, 0.94, 1.23, 3.19, 0.33, 0.93, 0.61,

8.18

0.46

3.2.2

Original VMAT plans
Clinically optimal HyperArc style single-isocenter VMAT SRS plans were

generated in the Eclipse TPS for the Truebeam Linac (Varian Medical Systems, Palo Alto,
CA) with standard millennium MLC and 10MV-FFF beam (maximum achievable dose
rate of 2400 MU/min). The plans mimicked HA-VMAT geometry consisting of 4 VMAT
arcs: one 360o axial arc and three 180o non-coplanar half arcs at couch positions of 45o,
90o, and 315o (IEC convention). 9The isocenter was placed at the approximate geometric
center of all the tumors. The collimator angles were chosen manually to minimize island
blocking and dose outside of the target. Dose was 20 Gy to each lesion prescribed to 7080% isodose line. The plans were optimized so that 95% of each PTV received at least
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100% of the prescription dose with the hotspot at the center of the GTV. The dose was
calculated with Anisotropic Analytic Algorithm (AAA) (Eclipse, version 15.6) with 1.25
mm calculation grid size. Inverse optimization was performed with the photon optimizer
(PO) MLC algorithm with individual dose steering ring structures to each target. Jaw
tracking and normal tissue objective (NTO) was used to control the dose fall-off outside of
each target for better dose conformity and sparing the adjacent OAR. Planning objectives
followed RTOG 0933 guidelines for hippocampal sparing that were converted to SRS dose
constraints using biological effective dose, allowing maximal dose to hippocampus to be a
max dose of < 6.5 Gy . 24-25Other OAR followed QUANTEC guidelines for single fraction
treatments such as maximal dose to optic apparatus < 8.0 Gy. 26
3.2.3

DCA-VMAT plans
For comparison, the original VMAT plans for all patients were retrospectively re-

planned (in Eclipse version 15.6) using a new feature (MLC aperture controller) with DCAbased dose calculation followed by VMAT optimization (DCA-VMAT). Figure 3.1 shows
the proposed treatment planning workflow of this novel approach.22 For the DCA-VMAT
plans (with identical beam geometry), first 1mm of the MLC aperture around the combined
PTV is automatically generated and maintained dynamically around the targets during arc
rotation. The MLC fitting was observed to dynamically conform to the beam’s-eye-view
(BEV) projections of the combined PTV for each arc. Second, a high priority in the MLC
aperture shape controller was selected (a new feature in Eclipse v15.6, PO MLC algorithm
in calculation models) and proceeded to calculate a DCA-based 3D dose distribution. This
3D dose distribution was then used as a based-dose for VMAT optimization. This was
followed by VMAT optimization with identical planning objectives, dose calculation
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algorithm, grid-size and convergence mode identical to the original VMAT plan, including
the normal tissue objectives (NTO) parameters and ring structures.

Figure 3.1 Treatment planning workflow of DCA-VMAT method for multiple brain
metastases
3.2.4

Plan evaluation and data analysis
This study was a retrospective planning study and none of the patients were treated

with the DCA-VMAT or original VMAT plans. The DCA-VMAT plans were compared to
the original VMAT plans for minimum, mean and maximum dose to each GTV. The
combined PTV coverage was assessed by comparing with original PTV D95% coverage
and conformity index (CI). The low and intermediate dose-spillage to the normal brain was
evaluated by V30% and V50% for brain minus combined PTV in addition to mean brain
dose (MBD), V8Gy and V12Gy. V30% and V50% were defined as the volume of brain
minus combined PTV receiving greater than or equal to 30% and 50% of the prescribed
dose, respectively. The OAR were evaluated using their maximal doses to hippocampi,
brainstem, and optics apparatus. Comparing total number of monitor units (MU), beam
modulation factor (MF) and total beam on time (BOT) evaluated the treatment delivery
efficiency. The MF was defined as the ratio of total number of total MU to the prescription
dose in cGy. The BOT was recorded during VMAT quality assurance (QA) phantom
measurement at the machine for both plans. Dosimetric verification of the both plans were
performed by using portal dosimetry (PD) QA procedure established in our clinic.30 The
electronic portal imaging device (EPID, aS1200 flat panel detector, Varian Medical
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Systems) mounted on the Truebeam Linac was used. The detector has an active area of 400
mm × 400 mm with a very high resolution pixel size of 0.34 mm. A paired two‐tail
student’s t‐test (Microsoft Excel, Microsoft Corp., Redmond, WA) was used to compare
the data for the original VMAT vs DCA-VMAT plans for all dosimetric parameters of
target coverage, dose to OAR and treatment delivery parameters. A p-value below 0.05
was considered to indicate statistically significant.

3.3
3.3.1

Results
Target coverage and dose to normal brain
Compared to original VMAT plans, DCA-VMAT plans provided similar tumor

conformity, target coverage and comparable dose to GTV; all exhibited no statistical
significance differences. However, DCA-VMAT plans shows smaller values of V30% (p
= 0.009) and V50% (p = 0.043) as demonstrated by the values of low and intermediate
dose-spillage to the normal brain (Table 3.2), systematically lower for all patient’s plans.
Table 3.2 Evaluation of target coverage and dose spill for all 7 patients
Parameters Original VMAT
DCA-VMAT
Combined
PTV

% Volume
covered by
Rx dose (%)

98.2 ± 0.9 (97.3–

97.8 ± 0.6 (96.8–

99.3)

98.6)

CI

1.23 ± 0.1 (1.15–

1.25 ± 0.1 (1.14–

1.29)

1.31)

48

p-value
p = 0.261

p = 0.228

Table 3.2 (Continued)
Low/interme V30% (cc)
diate dosespillage

GTV

V50% (cc)

Dmin (Gy)

Dmax (Gy)

352.7 ± 202.2

267.2 ± 146.8 (59.4–

(58.7–557.5)

414.9)

104.3 ± 56.7 (21.6–

88.9 ± 50.7 (19.6–

182.3)

164.0)

21.4 ± 0.73 (18.9–

21.2 ± 0.94 (18.7–

22.4)

22.8)

26.4 ± 4.6 (24.5–

25.7 ± 0.56 (24.7–

52.7)

26.8)

p = 0.009

p = 0.043

p = 0.762

p = 0.469

Figure 3.2 shows an example case of radiosurgical dose distribution of a patient
with 6 brain lesions in the axial, coronal, and sagittal views comparing the DCA-VMAT
(left panel) and the original VMAT (right panel). It was observed that clinically desirable
tighter 50% isodose distribution was obtained with DCA-VMAT (see blue 10 Gy isodose
lines) compared to the original VMAT plan. DVH parameters (top middle panel) are shown
for the GTVs, combined PTV coverage, and dose to OAR for DCA-VMAT plan vs the
original VMAT, suggesting that DCA-VMAT plan was dosimetrically superior. The
combined PTV size was 12.38 cc. In this case, the PTV coverage, CI, V30%, and V50%
were 98.6% vs 98.6%, 1.27 vs 1.25, 362.2 cc vs 512.4 cc and 87.9 cc vs 139.5 cc for DCAVMAT vs original VMAT plan, respectively. Moreover, V8Gy, V12Gy and MBD were
160.8 cc vs 255.5 cc, 39.7 cc vs 55.3 cc and 4.42 Gy vs 5.34 Gy for DCA-VMAT vs original
VMAT plan –all dosimetric parameters favoring the DCA-VMAT plan.
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Figure 3.2 Comparison of DCA-VMAT and original VMAT dose distributions for
example case #5
Side-by-side comparison of DCA-VMAT (left panel) and original VMAT (right panel)
planned dose distributions on axial, coronal and sagittal views for an example case #5 with
6 brain lesions. Each lesion was prescribed for 20 Gy to the PTV. Hippocampi (yellow)
contour and Middle: DVH of combined PTV (orange), 6 GTVs (red), brainstem (green)
and normal brain tissue (sea blue) for both plans is shown. Triangle shows the original
VMAT and square shows the DCA-VMAT plan. Identical target coverage, yet lower dose
to normal brain was achieved with DCA-VMAT plan; it provided lower values of V30%
and V50%, a shorter treatment time, and perhaps more accurate treatment delivery.
Figure 3.3 depicts the ratio of MBD, V8 and V12 between original VMAT and
DCA-VMAT plans. For all parameters, DCA-VMAT was favorable over original VMAT
plans and it was lower by 1.0 Gy (MBD), 44.5 cc (V8) and 4 cc (V12), on average,
respectively. Additionally, the maximal dose differences between the original VMAT and
DCA-VMAT plans for the OAR (optics apparatus, brainstem and hippocampus) were
found to be very small (not shown here) and therefore are not expected to be clinically
significant.
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Figure 3.3 Comparison of MBD, V8 and V12 between original VMAT and DCAVMAT
Ratio of MBD, V8 and V12 between the original VMAT and DCA-VMAT plans. MBD,
V8 and V12 improved by a 13%, 28% and 10%, on average respectively, corresponds to
1.0 Gy, 44.5 cc and 4.0 cc lowered with DCA-VMAT plan.
3.3.2

Treatment delivery efficiency and accuracy
Dose delivery efficiency was accessed by comparing total number of MU and

estimated beam on time while delivering QA plans at the machine. Compared to original
VMAT plans, DCA-VMAT plans show fewer total MU and less beam modulation. Mean
values of total MU and MF were 12498 and 6.3 for original VMAT plans vs 5742 and 2.9
for DCA-VMAT plans. The MF and the beam-on time for original VMAT vs DCA-VMAT
plans is shown in Figure 3.4. For the given DCA-VMAT plans, the total number of MU
was reduced significantly (by a factor of 2.2, on average, and systematically lower for all
patients) while using DCA-based dose before VMAT plan optimization, suggesting that
the DCA-VMAT plan had much smaller MF (p < 0.001). Because of this, the average
beam-on time for DCA-VMAT plan was 2.82 min less (p < 0.001) (maximum up to 3.8
min) than original VMAT plan (mean value, 6.21 min) due to less beam modulation
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through the multiple targets. With DCA-VMAT plan, single-dose of 20 Gy SRS treatment
to multiple brain lesions can be delivered in less than 3 min, on average. The lower beamon time will reduce the time the patient is on the treatment table, thus improving patient
compliance and potentially improving the clinic workflow.

Figure 3.4 Comparison of treatment parameters for original VMAT and DCAVMAT
Left panel: MF for DCA-VMAT vs original VMAT plans for all 7 patients with 2-8
multiple brain lesions (total 35 lesions). Mean values of MF for DCA-VMAT and original
VMAT plans were 2.87 ± 0.75 (ranged, 1.95–4.19) and 6.15 ± 1.25 (ranged, 3.62–7.22)
respectively. Right panel: The corresponding BOT for both plans. Mean values of BOT for
DCA-VMAT vs original VMAT plans were 3.39 ± 0.63 min (ranged, 2.63–4.49 min) and
6.21 ± 1.05 min (ranged, 4.01–7.86 min) respectively, with DCA-VMAT plans beam-on
time improve by an almost a factor of 2.0.
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Figure 3.5 Portal dosimetry QA results for original VMAT plan and DCA VMAT
plan for patient #5
Measured (red and orange) and calculated (blue and green) composite 2D profiles and
gamma pass rate (GPR) on portal dosimetry QA results of DCA-VMAT and original
VMAT plan for an example patient #5 who presented with 6 brain lesions. In this case,
8.5% improvement in GPR for 1%/1mm criteria with DCA-VMAT plan suggesting that
more accurate treatment delivery.
Treatment delivery accuracy was evaluated by delivering both plans at Truebeam
Linac in the QA mode using the EPID device and measuring the portal dosimetry QA data
(see example case #5 in Figure 3.5). The dose delivery accuracy of these original VMAT
plans, and the corresponding DCA-VMAT plans were 87.5 ± 4.3% (ranged, 81.9–94.7%)
and 95.4 ± 2.5% (ranged, 90.6–98.0%), on average respectively with 1%/1mm global
gamma passing rate criteria with a low-dose threshold of 10%. Due to the small pixel size
of aS1200 EPID detector (0.34 mm), the 2%/2mm gamma criteria was not very useful to
see the dosimetric differences for these small brain lesions, therefore our departmental
policy is to use 1%/1mm gamma criteria. One of seven cases met our departmental QA
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pass criteria of greater than 90.0% gamma pass rates for original VMAT plans, whereas all
seven cases met that criteria for DCA-VMAT plans, suggesting significantly improving
dose delivery accuracy for small brain lesions. In some cases (for small lesions) dose
delivery accuracy was improved by up to 13.6% with DCA-VMAT plans–suggesting that
significant dose deviation (p < 0.003) can be seen with highly modulated original VMAT
plans compared to DCA-VMAT plans.

3.4

Discussion
We have presented a novel and clinically attractive DCA-based single-isocenter

VMAT planning approach for multiple brain lesions. The new DCA-VMAT plans
achieved similar conformity and target coverage (see table 3.2) compared to original
VMAT plans. For all patients, the DCA-VMAT plans provided lower values of low and
intermediate dose spillage to normal brain, significantly reducing V30% and V50%.
Additionally, MBD, V8 and V12 were systematically lower with DCA-VMAT plans
including maximal doses to brainstem, optic apparatus and hippocampi. The DCA-VMAT
plans required less total number of MU to deliver the same total prescribed dose due to less
beam modulation through the multiple small brain lesions. Thus the BOT was reduced
significantly (average beam on time 3.0 minutes) demonstrating the clinical efficiency of
DCA-VMAT plans for treating multiple brain lesions simultaneously in this cohort.
Moreover, the treatment delivery accuracy was improved significantly with measured data
analyzed at 1%/1mm gamma passing-criteria, suggesting better delivery accuracy.
Liu et al presented dosimetric comparison of two competing technologies
BrainLAB MME vs Varian HyperArc VMAT for multiple brain metastases in a most
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recent study.

17

Thirty patients with 4-10 metastases were used. Both techniques used

single-isocenter with 2.5 mm high-definition MLC (HD-MLC). MME plans used 4-9 noncoplanar DCAs with 6MV-FFF beam where as HyperArc used 2-4 non-coplanar VMAT
arcs with 10MV-FFF beam. They have concluded that HyperArc VMAT favors better
target conformity and high- to moderate dose levels compared to MME DCA plan while
MME DCA gave slightly favorable low isodose spills. Approximate average beam on time
for both techniques was reported, however they did not mention how this was achieved.
6MV-FFF beam of non-uniform dose profiles was managed while calculating MME DCA
plan. Our clinical experience is generating DCA plans for multiple brain lesions with 6MVFFF beam will be very challenging to get the highly conformal dose distribution around
the targets due to uneven dose profiles. Moreover, the MLC complexity and the QA pass
rates for HyperArc VMAT were not reported. Similar to HyperArc plans, we used 10MVFFF beam but in contrast, we have presented the better treatment delivery efficiency and
accuracy by delivering each DCA-VMAT plan with PD QA at the treatment machine.
Multiple researchers have studied the sparing of normal brain V8-V12 dose 25 and
other OAR including hippocampi for SRS treatment of multiple brain metastases with or
without WBRT and simultaneous integrated boost dosing. 24, 27-29For instance, Birer et al.
demonstrated lower maximal dose to hippocampi (< 6.5 Gy) can be achieved while reoptimizing previously treated SRS patients with 4-10 lesions via single-isocenter VMAT
plan and potentially improve neurocognition deficit. In this setting, incorporating this novel
DCA-VMAT approach can further minimize normal brain dose and other OAR including
the hippocampi. However, there are few limitations of this retrospective study need to
mention. First, due to the lack of HyperArc planning license, we have created HyperArc
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style VMAT plans using a single-isocenter VMAT technique. Although, the arc geometry
of HyperArc was kept identical, collimator optimizations were done manually to minimize
the out of field dose on a per-patient basis. Second, HyperArc VMAT for multiple brain
lesions is primarily used to linear accelerators utilizing 2.5 mm HD-MLC. Due to the
unavailability of HD-MLC, our HyperArc style single-isocenter VMAT plans were
generated using standard millennium 5 mm width MLC at Truebeam Linac. However,
multiple recent studies

31, 32

have demonstrated that for radiosurgery of multiple brain

metastases using a single-isocenter VMAT plan with 5 mm MLC can produce similar target
conformity of HD-MLC with a slight increase in 30-50% isodose spillage, but can be
managed by adding one or two more VMAT arcs. 31
In summary, the potential benefit of utilizing DCA-based planning for HyperArc
style single-isocenter VMAT for multiple brain lesions has been presented. With this
approach, DCA-based plan optimization potentially reduces MLC complexity and beamon time while providing similar target coverage to multiple lesions and lower dose to
normal brain and other OAR in the brain. Therefore, to minimize MLC complexity and
subsequently improve treatment delivery efficiency and accuracy we strongly recommend
utilizing DCA-VMAT approach (if available) for single-isocenter/multi-lesions VMAT
optimization, thereby reducing the total number of MU, MLC leakage and transmission
and potentially lowering unwanted dose to the patients. The lower BOT will reduce the
time the patient is on the treatment table, thus improving patient compliance and potentially
improving the clinic workflow. Our future research incudes incorporating this novel DCAbased approach for generating better quality HyperArc VMAT plans for multiple brain
lesions.
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3.5

Conclusions
Our results clearly indicates that the advantages of using DCA-based approach in

VMAT optimization for single-isocenter HyperArc style planning in the treatment of
multiple brain lesions in terms of generating low- and intermediate dose to normal brain.
With DCA-VMAT plan, the total number of MU, complexity of MLC patterns, and beamon time was reduced significantly. Higher QA pass rates indicates that safe and more
accurate treatment can be delivered. Incorporating DCA-based dose method in HyperArc
module in future could further improve plan quality, treatment delivery efficiency and
accuracy of multiple brain metastatic patients and hence improving the patient comfort and
clinic workflow.
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CHAPTER 4. A NOVEL RISK ADAPTED SINGLE ISOCENTER VMAT PLANNING TECHNIQUE
FOR RADIOSURGERY OF MULTIPLE BRAIN LESIONS TO MINIMIZE SPATIAL SETUP
UNCERTAINTIES

Due to the dosimetric errors due to patient positioning uncertainty discussed in Chapter
1 and 2, correction strategies to improve accuracy in the SIMT VMAT setting was
explored. A risk adapted treatment technique was introduced to accomplish this goal. With
this technique, small lesions at high risk due to their distance to isocenter would receive a
higher prescription dose (24 Gy), where lesions close to critical structures would receive a
lower prescription (18 Gy). Other lesions would receive a nominal prescription dose (20
Gy). The results of this chapter provided a treatment method to help improve the accuracy
of SIMT VMAT techniques. This chapter has been adopted from the recently submitted
manuscript for peer review by: Palmiero A, St. Clair W, Randall M and Pokhrel D. “A
Novel Risk Adapted Single Isocenter VMAT Planning Technique for Radiosurgery of
Multiple Brain Lesions to Minimize Spatial Setup Uncertainties. J Appl Clin Med Phys.
(Under Review, Submitted November 2020)
Abstract
Purpose: Treating multiple brain lesions synchronously using a single-isocenter
volumetric modulated arc therapy (VMAT) stereotactic radiosurgery (SRS) plan could
significantly improve treatment delivery efficiency, patient compliance and clinic
workflow. However, due to spatial set up uncertainty, aligning multiple brain lesions on a
single daily conebeam CT (CBCT) is associated with unacceptable loss of target(s)
coverage. To date, this issue has been managed by adding additional margin around the
tumors, however this could increase dose to organs-at-risk (OAR) and the risk of brain
toxicity. In contrast, we propose a novel risk-adapted correction strategy: an alternative
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treatment planning approach that escalates dose to tumors away from the isocenter,
compensating for setup errors. This planning method utilizes user defined aperture shape
controller and dynamic conformal arcs-based dose calculation before VMAT optimization.
Methods: Seven difficult cases with 3-16 lesions (57 tumors) were planned with a singleisocenter VMAT-SRS (original VMAT) using a 10MV-FFF beam for a nominal singledose of 20 Gy to each lesion. To compensate for the loss of target(s) coverage due to
geometric setup errors and spare the OAR, each plan was re-planned using a risk-adapted
approach (risk-adapted VMAT), utilizing 3-prescription (18 Gy, 20 Gy and 24 Gy) based
on: distance to isocenter, tumor size and proximity to the OAR.
Results: Compared to original VMAT, risk-adapted VMAT plans provided similar target
coverage and dose conformity and lower dose to normal brain and adjacent OAR. Most
importantly, it compensated for the loss of target(s) coverage for small lesions (17 of 57
tumors) away from isocenter and provided a nominal dose of 20 Gy or higher to each
lesion.
Conclusion: With less spread of intermediate dose to normal brain and similar treatment
delivery parameters, the risk-adapted VMAT plan with up to 1o/1 mm set up errors in all 6
directions demonstrated promising plan quality and treatment delivery accuracy for
patients with multiple brain lesions.

4.1

Introduction
Studies have demonstrated the feasibility of treatment of multiple intracranial

lesions using single-isocenter volumetric modulated arc therapy (VMAT) stereotactic
radiosurgery (SRS).1-4 To automate SRS treatment delivery, Varian introduced a Truebeam
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Linac-based (or superior) single-isocenter VMAT platform known as HyperArc as a
module in the Eclipse treatment planning system (TPS, Varian Medical Systems, Version
15.6).5-10 The major advantages of single-isocenter VMAT-SRS are reduction of treatment
times and improvement of patient comfort and clinic workflow. The main challenge of this
approach for treatment of multiple brain lesions is patient positioning and spatial
uncertainty during treatment. This geometric uncertainty due to rotational and translational
errors can generate a large dosimetric disparity on the total delivered dose compared to
traditional multi- isocenter methods as previously demonstrated.11-20 For instance, Palmiero
et al. performed a dosimetric study evaluating clinically observable treatment delivery
inaccuracies in all six-degrees-of-freedom (6DOF) of the couch, demonstrating potential
to under dose the target(s) up to 72% and increase dose to adjacent organs-at-risk (OAR).20
To resolve the issue, researchers have suggested adding an additional margin around the
lesions, including an asymmetric margin.11-18,19 For example, Ezzell analyzed the
feasibility and spatial accuracy of single-isocenter non-isocentric treatments to multiple
brain lesions using two image-guidance systems.16 As expected, spatial accuracy degrades
at large distances from isocenter and an additional tumor margin 1 mm at least 5 cm away
from the isocenter was recommended. However, adding additional margin around multiple
tumors could dose to OAR and increase toxicity.22-25 For linac-based SRS, frameless
thermoplastic mask systems are be viable options intracranial radiosurgery by
immobilizing the patient within 1 mm accuracy.26 However, this does not correct for
geometric set up errors. Moreover, small brain lesions cannot be seen on daily conebeam
CT images, and alignment must be made by rigid registration to bony landmarks. Aligning
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each lesion perfectly to the planning CT images is nearly impossible, creating dosimetric
deviation from the plan.
To tackle this problem, a novel correction strategy using a risk-adapted planning
approach is described where variable prescriptions are prescribed based on distance to
isocenter, tumor size. and proximity of the dose limiting OAR such as optic apparatus,
brainstem and hippocampus. The hypothesis is that by escalating prescription dose to 24
Gy, the loss of target(s) coverage to small lesions away from isocenter could be alleviated
without adding additional margin around the target(s). Similarly, prescribing 18 Gy to
larger tumors located near dose limiting OAR could be safer in the palliative multi-lesion
SRS setting, while other tumors could potentially receive higher doses. This can be
accomplished dynamic conformal arcs (DCA) based dose calculation and user defined
aperture shape controller features before VMAT optimization.27 The aim of this manuscript
is to demonstrate proof-of-concept of this novel correction strategy to minimizing the
dosimetric impacts of geometric errors in the treatment of multiple brain lesions using
single-isocenter VMAT.

4.2
4.2.1

Materials and Methods
Patient images and contouring
Seven previously treated SRS patients with multiple brain metastases were included

in this retrospective study with Institutional Review Board approval. Patients were
immobilized in the supine position with a thermoplastic mask and hands on chest. Patients
were imaged with a GE Lightspeed 16 slice CT scanner (General Electric Medical Systems,
Waukesha, WI) with a 512 × 512 pixel size and 1.25 mm slice thickness. Planning CT
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images were co-registered with high-definition (1 mm cuts) MPRAGE sequence MRI
images (Siemens MAGNETOM, 1.5T MRI System, Ferndale, MI) for target(s) and OAR
delineation. An radiation oncologist delineated the gross tumor volumes (GTVs) on the
MRI images co-registered to the planning CT images. The planning target volumes (PTVs)
were created as a 1 mm symmetric margin around the GTVs. There were 3 to 16 lesions
per patient and a total of 57 tumors. The OAR included the optic apparatus (optic nerves
and optic chiasm), brainstem, hippocampi (left and right hippocampus), and normal brain
tissue (brain minus PTVs). The hippocampi were contoured following RTOG 0933
guidance.22 Distance to isocenter was calculated by measuring the 3-dimentional Euclidean
distance with the coordinates of the geometric center of each PTV with respect to the
single-isocenter coordinates in Eclipse TPS.
4.2.2

Original VMAT plans
Single-isocenter VMAT SRS plans were generated in Eclipse TPS for the

Truebeam Linac (Varian Medical Systems, Palo Alto, CA) with standard millennium MLC
and 10 MV-FFF beam (maximum dose rate of 2400 MU/min). Four non-coplanar arcs were
used to mimic HyperArc style VMAT geometry. One full 360o arc and 3 non-coplanar
partial arcs were used to replicate the gantry motion and couch rotations. The single
isocenter was placed at approximately the geometric center of all the targets. Collimator
angles were manually chosen to minimize island blocking and low dose spillage.28,29
Twenty Gy to the 70-80% isodose line for each lesion; at least 95% of each target received
100% of the prescribed dose and the hotspot was at the center of the each GTV. All plans
were created with a DCA-based VMAT planning technique using the new MLC aperture
controller features in Eclipse as mentioned above.27 The combined PTV was created by
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summing all the PTVs. A 1 mm MLC aperture was first automatically formed around the
combined PTV and dynamically maintained during arc rotation, as observed in the beam’s
eye view (BEV) projection. A high priority aperture shape controller strength was then
assigned (Eclipse v15.6, Photon Optimizer (PO) MLC algorithm). The DCA-based dose
was calculated before VMAT optimization for appropriate target coverage and OAR
sparing. The dose was calculated with Anisotropic Analytic Algorithm (AAA) (Varian
Eclipse TPS, version 15.6) with the smallest calculation grid size (CGS) of 1.25 mm. On
the PO MLC configuration, individual ring structures for each target were used for dose
steering. Steep dose fall-off was enhanced by utilizing the jaw tracking option and normal
tissue objective (NTO). Hippocampi were spared by using planning objectives in RTOG
0933 corresponding to the effective biological single-fraction dose tolerances of < 6.5
Gy.22-23All other OAR tolerances followed QUANTEC guidelines for single-dose
treatments with a maximal doses to the optic apparatus and brainstem < 8.0 Gy and < 12.0
Gy, respectively.24
4.2.3

Risk Adapted VMAT plans
For comparison, all original VMAT plans were re-planned using risk-adapted

variable prescriptions based on distance to isocenter, target size and proximity to adjacent
OAR. Beam geometry was identical to the original VMAT plans including isocenter
location and the DCA-based planning approach with an identical strength of a user defined
aperture shape controller. Three prescriptions were utilized in this planning strategy; 18
Gy, 20 Gy and 24 Gy. For lesions, at risk of underdosage, the prescription dose was
escalated to 24 Gy if they met 3 criteria: greater than 5 cm away from the isocenter, smaller
than 5 cc volume and not proximate to a dose limiting OAR. Lesions close to OAR and
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bigger than 5 cc were prescribed a lower dose of 18 Gy. All other tumors were prescribed
a nominal 20 Gy to each lesion. In this patient cohort, 17 targets received 24 Gy, 11
received 18 Gy, and 29 received 20 Gy. These prescriptions were implemented in the
inverse optimization system using separate objectives for each target. The hot spots in the
center of the GTV and dose fall-off via ring structures were scaled according to the
prescription of the each target. All plans were re-optimized, so that at least 95% of each
target volume received 100% of the respective prescription dose, similar to the original
VMAT plan. The dose calculation algorithm, CGS, jaw tracking option and normal tissue
objective (NTO) were kept identical to the original VMAT plan.
4.2.4

Simulation of setup uncertainty
To quantify the dosimetric impacts of set up errors, the original VMAT and the

risk-adapted VMAT plans were simulated with induced patient setup uncertainties of
0.5°/0.5 mm, 1°/1 mm and 2°/2 mm in all 6 degrees-of-freedom (6DOF). The residual
translational errors were defined for isocenter displacements and the rotational errors were
defined for patient rotations relative to the isocenter position around the anterior/posterior
(pitch), left/right lateral (yaw) and superior/inferior (roll) directions. The simulation of set
up uncertainties was introduced using an in-house simulation method developed in
MATLAB (Mathworks Inc., WA, USA). All planning CT images were duplicated and coregistered to the original CT images, The image registration DICOM file was exported
from the Eclipse TPS and imported to a MATLAB script that generated all 3-rotational
(Δα, Δβ, Δγ) and translational (Δx, Δy, Δz) errors of 0.5°/0.5 mm, 1°/1 mm and 2°/2 mm.
These matrices were applied to the reference frame, simulating isocenter displacement in
all 6DOF. The new registration image DICOM file was imported into Eclipse. The original
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VMAT and risk-adapted VMAT plans were overlaid onto the new registered images and
dose was recalculated, with the only differences being the isocenter shift in all 6dimensions.
4.2.5

Plan evaluation
In this proof-of-concept retrospective study, none of the SRS patients were treated

with the original VMAT plan or the risk-adapted VMAT plan. Dosimetric impacts of
geometric set up errors was determined by comparing the target coverage and dose to OAR
between the original and the simulated plans. Differences in PTVD 95% coverage between
the plans determined the loss of target(s) coverage. The loss of target coverage between the
original VMAT and the risk-adapted VMAT plans were then compared. The minimum,
mean, and maximum doses to the GTV were evaluated and compared between the two
plans. The PTV and GTV coverages were assessed by the relative volume covered by the
prescription isodose line. Tumor dose heterogeneity index (HI) and conformity index (CI)
were calculated for each lesion per RTOG guidelines. The HI is the ratio between the
maximum dose in the target and the prescription dose to each lesion. A HI of less than 2.0
meets protocol guidelines. The CI is the ratio of the volume of the prescription isodose and
the volume of the PTV. A CI of 1.0 indicates superior plan conformity. The OAR doses
were evaluated by examining the maximal dose to the optic apparatus, brainstem and
hippocampi. Dose to normal brain was assessed for V8Gy, V12Gy, V16Gy and mean brain
dose (MBD) between the plans. Treatment deliverability was assessed by comparing the
total number of monitor units (MU), beam modulation factor (MF), total beam on time
(BOT) and estimated treatment time. The MF is the ratio of the total number of monitor
units to the prescription dose in cGy. The BOT was calculated as a ratio of the total MU
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and the maximum dose rate setting (2400 MU/min) for the 10 MV-FFF beam on Truebeam
Linac. The estimated treatment time accounted for daily single conebeam CT imaging,
image matching, couch kicks, beam preparation and BOT for each plan. It is assumed that
the 10 minutes for patient setup, conebeam CT time, and applying shifts and 5 minutes for
couch rotation time including therapists entering the treatment room. Statistical analysis
was performed using Microsoft Excel (Microsoft Corp, Redmond WA) program. Mean,
standard deviation (SD) and range values for each of the dose metrics were compared for
both plans.

4.3

Results
Differences in the target coverage for GTVs and PTVs are demonstrated in Figure

4.1. This result contains the targets that received 24 Gy (17 targets of 57) to observe
minimizing the risk of loss of target coverage due to isocenter misalignment. Coverage loss
was fully minimized for set up errors up to 1°/1 mm in any direction and could potentially
deliver nominal dose of 20 Gy those lesions. Coverage loss was greatly reduced for errors
up to 2°/2 mm for both the GTV and PTV (Figure 4.1). For 0.5°/0.5 mm induced setup
errors, the original loss of average target coverage was 0.04 ± 0.08% (0–0.2%) for GTV
and 8.2 ± 4.7% (0.93–15.8%) for the PTV and the corresponding risk-adapted plans had
no loss of target coverage (p < 0.001) for both the GTV and PTV. For 1°/1 mm induced
setup errors, the original plans had an average coverage loss of 5.5 ± 5.3% (0–16.8%) for
the GTV and 20.8 ± 11.4% (2.1–35.3%) for the PTV. The corresponding risk adapted plan
had no loss for the GTV (p < 0.001) and relatively smaller average loss of 3.4 ± 2.6% (0–
7.8%) (p < 0.001) for the PTV. However, for the induced 2°/2 mm setup errors, the original
VMAT plan showed an clinically unacceptable loss of 40.5 ± 24.6% (6.0–72.0%) for the
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GTV and 48.6 ± 17.1% (1.4–53.0%) for the PTV. For those larger shifts, the corresponding
risk adapted plans slightly improved the target coverage but still presented significant
dosimetry errors of 15.6 ± 13.2% (0–40.4%) (p < 0.001) for the GTV and 27.1 ± 17.1%
(1.4–53.0%) (p < 0.001) for the PTV, respectively. Significant differences were observed
in the loss of coverage for all induced setup uncertainties with any errors larger than 1°/1
mm.

Figure 4.1 Loss of target coverage for induced uncertainty in all 6DOF
Loss of target coverage with induced uncertainties of 0.5°/0.5 mm, 1°/1 mm, and 2°/2 mm
in all 6-directions. This cohort consists of 17 vulnerable targets receiving 24 Gy
prescription. The blue is the original VMAT and the red is the risk-adapted VMAT plans
with standard deviation error bars. Original, uncorrected VMAT plans showed clinically
unacceptable loss of target coverage for 1°/1 mm or less set up errors while the risk adapted
approach showed an improved coverage providing at least nominal dose of 20 Gy or higher
to each lesion.

Compared to the original VMAT, for similar PTV coverage, target conformity and
dose heterogeneity, the risked-adapted VMAT plans showed slightly increase maximum,
minimum and mean dose to the to the GTV, considered desirable in many SRS treatments.
With risk-adapted plan there was a significant reduction of V8Gy, V12Gy and MBD by
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107 cc, 28 cc and 1.0 Gy, on average, respectively, while providing similar V16Gy that
was due to escalated tumor dose to those small lesions farther away from the isocenter (see
Table 4.1).
Table 4.1 Target coverage and dose to normal brain for all 7 patients
Target(s)
Parameter
Original VMAT
Risk-adapted VMAT
GTVs
(n = 57)

Maximum

dose 24.9 ± 1.3 (22.3–26.8)

26.4 ± 2.5 (20.4–29.0)

dose 21.6 ± 0.59 (20.3–22.8)

22.5 ± 2.5 (18.0–26.7)

(Gy)
Minimum
(Gy)
Mean dose (Gy)

23.6 ± 0.88 (21.7–24.9)

24.9 ± 2.4 (20.3–29.0)

98.4 ± 1.1 (95.0–100.0)

97.9 ± 1.6 (95.0–100.0)

CI

0.98 ± 0.09 (0.90–1.2)

0.98 ± 0.09 (0.91–1.2)

HI

1.2 ± 0.7 (1.1–1.3)

1.1 ± 0.09 (1.02–1.3)

V8Gy (cc)

239.7 ± 221.8 (34.9– 132.6 ± 84.0 (53.6–

PTVs

% Volume

(n = 57)

Normal

covered by RX
dose (%)

brain

558.9)

249.0)

V12Gy (cc)

68.1 ± 58.3 (9.3–147.7)

40.7 ± 20.7 (16.5–71.3)

V16Gy (cc)

11.7 ± 6.0 (2.4–19.6)

13.5 ± 5.4 (6.0–20.9)

MBD (Gy)

4.8 ± 2.3 (2.4–8.0)

3.9 ± 1.5 (1.9–5.7)

Table 4.2 shows the number of lesions per patient and the average 3D Euclidian
distance between the target and the single isocenter for each patient ranged from 4.5 cm to
5.5 cm. In this cohort, 11 of 57 targets were determined to be proximal to the OAR (optic
68

apparatus, brainstem and hippocampus). With risk-adapted planning approach, for each
patient the dose to OAR was reduced systematically and kept below the SRS protocol
requirements.
Table 4.2 Maximum dose to adjacent critical isocenter and tumor distance to
isocenter
Patient No. of
Average
Dose
Maximal dose to adjacent OAR
no.

lesions

distance to

limiting

isocenter

OAR

(cm)

Original

Risk-adapted

VMAT (Gy)

VMAT (Gy)

I

3

4.6

Hippocampi

10.6

6.2

II

4

4.7

Optic

11.3

6.4

apparatus
III

5

3.5

Hippocampi

6.1

5.6

IV

8

5.4

Optic

10.2

6.7

Hippocampi

6.6

5.1

Brainstem

15.9

11.8

Hippocampi

15.3

7.1

apparatus

V

11

5.5

VI

11

5.0

Hippocampi

15.4

8.2

VII

16

5.4

Optic

7.2

4.7

Hippocampi

10.6

6.2

Brainstem

11.6

8.1

apparatus
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Figure 4.2 shows an example (case #5) of the original VMAT plan of a patient who
presented with 11 brain lesions. Dose distributions are displayed in axial, coronal and
sagittal views. This can be compared to the same dose distributions for the risk-adapted
VMAT plan, shown in Figure 4.3. The original VMAT plan had a single prescription dose
of 20 Gy to all lesions, whereas the risk-adapted VMAT plan was generated for 3
prescriptions as described above, which is evident in the isodose color wash. Both the
coronal and axial views in Figure 4.3 show a lower isodose spread into the hippocampus
and brainstem, explaining the decreases in dose to critical structures in the risk-adapted
VMAT plans as compared to the original VMAT plan (see Figure 4.2). Lesions at a farther
distance from isocenter is displayed in the all 3 views, providing an example of the lesions
that would have an escalated prescription dose of 24 Gy in the risk-adapted VMAT plan.
The higher level of intermediate dose bridging that is obvious in the coronal view of the
original VMAT plan, was mitigated with a tighter 50% isodose distribution is evident in
the risk-adapted approach.
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Figure 4.2 Example patient #5 single prescription plan
Example of the original VMAT plan with a nominal single-dose of 20 Gy to each lesion
for an patient #5. The top panel shows the isodose colorwash in axial, coronal and sagittal
views. The bottom panel contains the DVH for all PTVs (orange), GTVs (red), and the
OAR: hippocampus (pink), brainstem (blue) and optic apparatus (light green) including
normal brain (dark green).
Figures 4.2 and 4.3 can also be analyzed by their respective DVH for target
coverage and dose to OAR. Differences in prescription are evident for each lesion. The
original VMAT plan (Figure 4.2) has a single prescription of 20 Gy with all PTV (orange)
receiving at least 95% of the prescription dose with the GTV (red) consisting of a 120%
hotspot as described above. The risk-adapted plan has a lesion receiving 18 Gy (green
arrow) prescription dose due to the proximity of brainstem and hippocampus. Four of 11
lesions were planned for the nominal dose of 20 Gy (blue arrow). Six lesions had an
escalated prescription dose of 24 Gy (black arrow) due to distance from isocenter of > 5
cm. Additionally, dose to optic apparatus (green), brainstem (blue) and hippocampus (pink)
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were reduced significantly compared to Figure 4.2 (see Table 4.2). The maximum dose to
the optic apparatus, brainstem and hippocampus were 6.5 Gy, 15.9 Gy and 15.3 Gy for the
original VMAT, respectively, and 3.5 Gy, 11.8 Gy and 7.1 Gy for the risk-adapted VMAT
plan, respectively. Dose to normal brain was also reduced. Brain V8, V12 and MBD were
18.4 cc, 5.3 cc and 4.8 Gy, respectively, for the original VMAT plan, while the risk adapted
plans were 9.4 cc, 3.0 cc, and 3.9 Gy, respectively.

Figure 4.3 Example patient #5 with risk adapted plan
Example of the risk-adapted VMAT plan with 3 prescriptions (same patients with 11
lesions shown in Figure 4.2). Dose distributions on the axial, coronal and sagittal views are
displayed (top panel) corresponding to the DVH (bottom panel). The PTVs (orange), GTVs
(red), hippocampus (pink), optic apparatus (green) and brainstem (blue) including normal
brain (dark green) are shown, demonstrating sparing of OAR with acceptable target
coverage. Normal brain receives less dose than the original VMAT plan (Figure 4.2).
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Table 4.3 shows the comparison of the treatment delivery parameters for the two
plans. The risk-adapted VMAT had similar total MU, beam MF, BOT and estimated
overall treatment time.
Table 4.3 Treatment delivery parameters for all 7 patients
Treatment delivery
Original VMAT
Risk-adapted VMAT
parameters
Total MU

90182 ± 2741 (5400–

8959 ± 2879 (5247–12444)

13064)
Modulation factor (MF)

4.6±1.4 (2.7–6.5)

4.3 ± 1.3 (2.4–5.7)

Beam-on time (min)

3.8 ± 1.1 (2.3–5.4)

3.7 ± 1.2 (2.2–5.2)

Treatment time (min)

18.8 ± 1.1 (17.3–20.4)

18.7 ± 1.2 (17.2–20.2)

4.4

Discussion
A novel and clinically useful risk-adapted single-isocenter VMAT planning

approach is presented to minimize the effects of set up errors for targets at some distance
from the isocenter and without adding additional tumor margin. Utilizing a DCA-based
approach, risk-adapted VMAT plans provided better plan quality, lower dose to normal
brain and spare relevant critical structures. Escalating dose to small targets that are prone
to uncertainty improves target coverage, providing at least a nominal prescription dose of
20 Gy for spatial uncertainties up to 1°/1 mm, and greatly improves coverage for those up
to 2°/2 mm. However, larger set up errors of 2°/2 mm, repositioning the patient, repeating
the conebeam CT scan and realigning the lesions is preferred. In addition to more
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appropriate doses to the GTVs (due to the escalated prescription), the risk-adapted VMAT
plan provided lower MBD, V8Gy and V12 Gy, potentially reducing brain toxicity.25
Researchers have studied potential correction strategies for dosimetric uncertainties
that come with treating multiple brain metastases with single-isocenter SRS techniques.2021

Most strategies suggest adding additional margin to compensate for inaccuracies, but this

has potential to increase brain necrosis.25A risk-adapted approach, as evaluated in this
study, is an alternative approach to compensate the loss of target coverage while limiting
dose to normal brain and other OAR. By correcting for these geometric inaccuracies and
minimizing dose to normal tissues, linac-based single isocenter VMAT SRS becomes a
safe, efficient, and effective treatment for selected patients with multiple brain metastases.
There are limitations to this study’s conclusions and applicability. Similar to
HyperArc VMAT geometry a problem of island blocking is presented while treating large
numbers of multiple brain lesions via a single isocenter VMAT plan, due to proximity of
the brain lesions. This means that two or more lesions share the same MLC pairs.28, 29 This
increases the spread of the low and intermediate dose, creating dose bridging between
targets. In the method reported here, this is minimized by manually choosing the best
collimator angle applied to each arc, but with a large number of lesions there is no currently
available way to completely alleviate this problem. Minimizing the spread of low and
intermediate dose-spillage in the treatment of multiple brain lesions via dual-isocenter
VMAT plans merits further investigation.31 Utilizing risk-adapted approach on dual
isocenter VMAT plans for treating left-sided vs right-sided brain lesions and only utilizing
the corresponding partial arcs would help minimize intermediate dose bridging. However,
dual-isocenter VMAT plans will increase planning time and approximately double the
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treatment time. Another limitation is that this study uses standard millennium MLCs (5
mm), whereas micro MLCs (2.5 mm) are recommended for best practice of linac based
SRS. 30 Utilizing a micro-MLC on risk-adapted VMAT plans with DCA-based approach
could generate highly conformal dose distribution, reduce dose bridging, and spare dose to
OAR in the treatment of multiple brain lesions, allowing dose escalation to smaller lesions
farther away from isocenter in single isocenter VMAT setting.

4.5

Conclusion
The results of this study support the use of a risk-adapted planning approach for

single-isocenter VMAT treatments for multiple brain metastases by accounting and
correcting for geometric set up errors. With this risk-adapted method, patients with larger
number of multiple brain lesions at reasonable distances from isocenter can be managed,
while maintaining similar plan quality, lower dose to normal brain and OAR. By
incorporating micro-MLC in the risk-adapted method, single-isocenter VMAT-SRS can
provide high quality SRS treatments to patients in an efficient manner.
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CHAPTER 5. MANAGEMENT OF MULTIPLE BRAIN METASTASES VIA DUAL ISOCENTER
VMAT STEREOTACTIC RADIOSURGERY

To manage the complex patients with a large number of brain metastases, another
correction strategy was introduced to minimize the dosimetric errors due to patient
positioning uncertainty in the SIMT VMAT approaches as discussed previously. Rather
than the traditional single isocenter plan to treat all lesions together, this novel dual
isocenter technique utilizing DCA-based VMAT optimization was introduced to
selectively treat lesions in groups to improve accuracy and plan quality of these treatment
techniques. Moreover, This technique was created to limit MLC travel distance by
restricting the tumor to isocenter distance, improve localization by reducing the region of
interest for CBCT matching and reducing dose to brain by minimizing island blocking. The
results of this chapter provide recommendations to physicians to manage difficult patients
with a large number of brain lesions. This chapter has been adopted from the recently
accepted manuscript by: Palmiero A, Fabian D St. Clair W, Randall M and Pokhrel D.
“Management of Multiple Brain Metastases via Dual Isocenter VMAT Stereotactic
Radiosurgery.” Med Dosim; 2020:1-7 (Article in Press)
Abstract
Single-isocenter volumetric modulated arc therapy (VMAT) stereotactic
radiosurgery (SRS) techniques to treat multiple brain metastases simultaneously can
significantly improve treatment delivery efficiency, patient compliance and clinic
workflow. However, due to large number of brain metastases sharing the same MLC pair
causing island blocking. This provides higher low and intermediate dose spillage to the
brain and higher dose to organs-at-risk (OAR). To minimize this problem and improve plan
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quality, this study proposes a dual isocenter planning strategy that groups lesions based on
hemisphere location (left vs right sided) in the brain parenchyma, providing less island
blocking reducing the MLC travel. This technique offers simplified planning while also
increasing patient comfort and compliance by allowing for large number of brain
metastases to be treated in two groups. Seven complex patients with 5-16 metastases (64
total) were planned with a single-isocenter VMAT SRS technique using a 10MV-FFF
beam with a prescription of 20 Gy to each lesion. The isocenter was placed at the
approximate geometric center of the target. Each patient was re-planned using the dual
isocenter approach, generating 2 plans and placing each isocenter at the approximate
geometric center of the combined targets of each side with corresponding non-coplanar
partial arcs. Compared to single isocenter VMAT, dual isocenter VMAT plans provided
similar target coverage and dose conformity with less spread of intermediate dose to the
normal brain with reduction of dose to OAR. Reduction in total monitor units and beam on
time was observed, but due to the second isocenter setup, overall treatment time was
increased. Dual-isocenter VMAT-SRS planning for large number of multiple brain
metastases is a simplified approach that provides superior treatment options for patient
comfort and compliance who may not tolerate longer traditional treatment time as with
individual isocenters to each target. This planning technique significantly reduces the
amount of low and intermediate dose spillage, further sparing OAR and normal brain,
potentially improving target accuracy though localization of left vs right sided tumors for
each isocenter.
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5.1

Introduction
Single isocenter volumetric modulated arc therapy (VMAT) stereotactic

radiosurgery (SRS) has gained popularity due to its fast and effective treatment for
management of multiple brain metastases.1-4 Varian developed the HyperArc module in the
Eclipse (Varian Medical Systems, Version 15.6) treatment planning system (TPS) on the
Truebeam Linac based automated treatment method for multiple brain metastases
patients.5-10 Single isocenter SRS provides reduction of treatment times, improving patient
comfort and clinic workflow. There are challenges when treating multiple brain metastases
with single isocenter VMAT. There is a degree of patient positioning spatial uncertainty
during treatment due to rotational and translational errors, generating a large dosimetric
disparity compared to that of multi-isocentric methods.11-21 Many correction strategies
consist of increasing the margin around the tumors to compensate for setup uncertainty,
but this presents major concerns with brain dose.11-25 There are also issues with island
blocking where multiple lesions share the same MLC pairs causing a higher level of low
and intermediate dose spill.26 Ohira et. al performed a study dosimetrically comparing a
collimator optimized HyperArc VMAT plan and a non-collimator optimized HyperArc
VMAT plan.27 They determined that the collimator optimized plan reduced dose to brain
tissues with comparable OAR doses. Though researchers have suggested mitigating island
blocking via collimator angle optimization, it cannot be fully be alleviated when
considering a large number of targets for a single-isocenter plan. To overcome both
mentioned challenges for treating multiple brain metastases, Prentou et. al first introduced
a two isocenter planning technique using traditional VMAT planning methods. This
planning technique limits the distance to isocenter and showed to decrease spatial
uncertainty for less than 4 lesions, though ability to spare normal structures was
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inconclusive.28 There is room to further investigate and provide a simplified treatment
planning and delivery strategy using dual isocenter approach to reduce island blocking,
potentially leading to less low and intermediate dose spillage, spare OAR and reduce dose
to normal brain. The use of dynamic conformal arc (DCA)-based VMAT optimization with
user defined aperture controller strength have shown improve plan quality, reduce
intermediate dose spillage and increase delivery efficiency.30 Combining a dual isocenter
approach with non-coplanar partial arcs and DCA-VMAT could potentially improve plan
quality, reduce dose bridging between the tumors, spare OAR and improve target
localization accuracy of multiple brain lesions.
To alleviate the issues discussed of this many body problem, a novel dual isocenter
VMAT technique has been developed to manage multiple brain metastases. In this novel
approach, lesions are grouped and treated in halves based on hemisphere location (rightvs left-sided) in the brain parenchyma, utilizing appropriate non-coplanar partial arcs on
each side. By grouping the lesions and treating separately, MLC does not need to
excessively travel on each plan and the dose bridging due island blocking can be limited,
sparing OAR and reducing brain dose while maintaining optimal plan quality. As described
above, this technique incorporates DCA based dose calculation and user defined aperture
shape controller features before VMAT optimization, improving plan quality and reducing
the overall plan complexity resulting in a decrease monitor units (MU).
Rather than matching the entire skull on a single daily cone beam CT (CBCT),
selectively matching regions of interest (ROI) defined by hemispheres of the brain can
improve target localization accuracy. Treating with two isocenters can increase overall
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treatment time; however, each lesion groups can be treated separately to improve patient
compliance and maintain an efficient clinic workflow and reduce brain toxicity.

5.2
5.2.1

Materials and Methods
Treatment planning datasets
Seven previously treated SRS patients with 3 to 16 lesions per patient (64 total)

were chosen for this retrospective study with Institutional Review Board approval. The
average gross tumor volume (GTV) and planning tumor volume (PTV) size of 0.84 cc
(range: 0.02-9.0 cc) and 1.5 cc (range: 0.11-12cc). Patients were immobilized with a
thermoplastic mask in the supine position. Patients were imaged with a GE Lightspeed 16
slice CT scanner (General Electric Medical Systems, Waukesha, WI) with a 512 × 512
pixel size and 1.25 mm slice thickness. These images were then registered with MPRAGE
sequence MRI images (Siemens MAGNETOM, 1.5T MRI System, Ferndale, MI) with 1
mm slice thickness. The MRI images were used for GTV and OAR delineation performed
by a radiation oncologist along with OAR. The PTVs were created as a 1 mm symmetric
margin around the GTVs. The OAR of interest to this study were optic apparatus (optic
nerves and optic chiasm), brainstem, hippocampi (left and right hippocampus) and normal
brain tissue (brain minus PTVs). The hippocampi were contoured following RTOG 0933
protocol guidance.22 The PTVs were grouped and combined based on location in either the
left or right hemisphere of the brain. Distance to isocenter was calculated by measuring the
3-dimentional Euclidean distance with the centers of the targets and isocenter.
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5.2.2

Single isocenter VMAT plans
The original single-isocenter VMAT SRS plans were generated in the Eclipse TPS

for the Truebeam Linac (Varian Medical Systems, Palo Alto, CA) with standard
millennium MLC and 10MV-FFF beam (maximum dose rate of 2400 MU/min). HyperArc
style VMAT geometry was mimicked with one full arc and 3 partial noncoplanar arcs to
replicate gantry motion and couch arrangements with the isocenter at the approximate
geometric center of all targets giving an average distance of 5.3 cm (range: 0.05-8.5 cm).
Collimator angles were chosen to best alleviate affects of island blocking.26-27 The
prescription to each lesion is 20 Gy to the 70-80% isodose line and optimized so that at
least 95% of the target volume receives 100% of the dose. All plans were created with a
DCA-based VMAT hybrid technique. A 1mm MLC aperture was generated around a
combined PTV structure. The aperture shape controller (Eclipse v15.6, Photon Optimizer
(PO) MLC algorithm) was assigned a high priority and the DCA-based dose was calculated
before VMAT optimization.

30

The dose was calculated with Anisotropic Analytic

Algorithm (AAA) (Varian Eclipse TPS, version 15.6) with the smallest calculation grid
size (CGS) of 1.25 mm. Dose steering and fall-off was maintained by ring structures, jaw
tracking and normal tissue objective (NTO). Hippocampi was spared following RTOG
0933 protocol corresponding to effective biological single fraction maximum dose of < 6.5
Gy.22-23 The optic apparatus and brainstem were spared following QUANTEC guidelines
of < 8 Gy and < 12 Gy, respectively.24
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5.2.3

Dual isocenter VMAT plans
The single isocenter VMAT plans were all replanned using a Dual-isocenter

technique. This method is outlined in Figure 5.1. Targets were divided based on their
hemisphere (left or right) location in the brain. Combined PTV structures were made for
both the left and right sides (combined left PTV and combined right PTV). Separate plans
were generated for both the left and right sided combined PTVs with an isocenter placed
at the geometric center of each side with an average distance to isocenter of 4.7 cm (range:
1.4-8.0).
Each plan consisted of 3 non-coplanar partial arcs corresponding to the left or right
side of the brain. The optimal collimator angle was chosen for each plan to further minimize
island blocking. The MLC shaper controller and DCA-dose was calculated as described
above. The left isocenter plan was then optimized with ring structures, jaw tracking and
NTO as mentioned previously. The combined left PTV plan was then used as a based plan
when optimizing the combined right PTV plan and a final dose calculation was generated.
Finally, both plans were combined and renormalized into a Dual-isocenter VMAT plan
sum (see Figure 5.1).
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Figure 5.1 Treatment planning work flow for dual isocenter VMAT planning
5.2.4

Plan comparison
This is a retrospective study and none of the SRS patients were treated with the

single or dual isocenter VMAT plans. The minimum, mean and maximum dose of the GTV
were evaluated between the two planning methods. The PTVs were compared as functions
of D99 (Gy), maximum dose (Gy), mean dose (Gy) and conformity index (CI). The CI is
the ratio of the prescription isodose volume and the volume of the PTV where a value of
1.0 is considered superior plan conformity. The OAR were assessed using the maximal
dose to the optic apparatus, brainstem, and hippocampi. The dose to the brain was
evaluated with V8Gy, V12Gy, and mean brain dose (MBD). Additionally, V30% and
V50% were documented. Deliverability of the plans were compared using the total number
of monitor units (MU), the modulation factor (MF), beam-on time (BOT) and overall
treatment time. BOT was calculated using the ratio of the total MU and the maximum dose
rate setting (2400 MU/min). The overall treatment time was estimated including patient set
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up time, conebeam CT scanning time for each isocenter, image matching, couch kicks,
beam preparation and BOT. It is assumed that it takes about10 minutes for patient setup
and conebeam CT time, so 10 minutes for a single isocenter and 20 minutes for dualisocenter plan. Couch rotations from inside the room are estimated to be about 5 minutes.
Statistical analysis was performed using Microsoft Excel program (Microsoft Corp,
Redmond WA). Mean, standard deviation (SD) and range values for each of the metrics
were compared in each plan.

5.3

Results
Figures 5.2 and 5.3 show an example case of a patient that presented with 16 brain

lesions. In figure 5.1, the dose distribution is displayed in the axial, coronal, and sagittal
views. The top panel contains the single isocenter plan and the bottom is the dual isocenter
plan. In the coronal and sagittal views, the single isocenter plan shows higher dose spread
into the brainstem and hippocampi. All 3 views show a tighter 50% isodose distribution
signifying lower intermediate dose spillage. This is all further shown in the DVH (see
figure 5.3) of both the single isocenter plan (triangles) and the dual isocenter plan (squares)
superimposed on one another. There are decreases in dose to hippocampi, optics apparatus,
brainstem and normal brain. For this example patient’s single isocenter plan, the maximal
dose to the hippocampi, optic apparatus and brainstem were 10.6 Gy, 9.6 Gy and 11.3 Gy
with a normal brain V8Gy, V12Gy and MBD of 402.3 cc, 47.0 cc and 5.2 Gy, respectively.
For the dual isocenter plan, the maximal dose the hippocampi, optics apparatus and
brainstem were 6.8 Gy, 5.1 Gy, and 8.3 Gy with a normal brain V8Gy, V12Gy and MBD
of 153.3 cc, 45.0 cc and 4.2 Gy, respectively. The PTVs were divided based on the left
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(purple) and right (orange) hemispheres of the brain. All PTVs received at least 95% of the
prescription dose with a 120% hot spot to each lesion (see figure 5.3).

Figure 5.2 Example case with 16 lesions.
Example case with 16 lesions with a prescription of 20 Gy to each lesion. The top panel
shows the isodose color wash (50 to 125%) in the axial, coronal and sagittal views for the
single isocenter plan. The bottom panel contains the isodose color wash in the same 3 views
for the dual isocenter plan. The dual isocenter plan demonstrates better sparing of
hippocampi (pink), brainstem (dark blue) and normal brain (dark green) with a lower
intermediate dose spread.
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Figure 5.3 DVH of example patient with 16 lesions
DVH of same example patient with 16 lesions for both the single isocenter plan (triangles)
and dual isocenter plan (squares). The combined-left PTV (purple) and combined-right
PTV (orange) received at least 95% of the prescription dose (20 Gy); all GTVs (red)
received higher dose. Decreases in maximal dose to hippocampi (pink), optics apparatus
(light green) and brainstem (dark blue) is evident. Major reduction of normal brain (dark
green) dose < 12 Gy is clearly demonstrated. The dual isocenter plan demonstrates better
sparing of OAR and decreases to dose normal brain while maintaining target coverage.
Compared to the single isocenter VMAT plan, the dual isocenter plan showed
similar minimum and mean dose to the GTV, with a slightly increased maximum dose,
which is advantageous to SRS plans. The dual isocenter also showed to have similar target
coverage, similar near minimum dose PTVD99%, maximum dose, mean dose and target
conformity of the PTV compared to the single isocenter plan (see Table 5.1).
Table 5.1 Evaluation of plan quality for all 7 patients for both single and dual
isocenter VMAT plans
Target(s)
Parameter
Single isocenter VMAT
Dual isocenter VMAT
GTVs

Maximum dose (Gy)

24.9 ± 1.3 (22.2–26.8)

25.3 ± 1.0 (21.3–25.7)

(n = 64)

Minimum dose (Gy)

21.4 ± 0.69 (20.3–23.3)

21.6 ± 0.72 (20.2–23.5)

Mean dose (Gy)

23.4 ± 0.9 (21.6–25.1)

23.8 ± 0.81 (21.3–25.7)
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Table 5.1 (Continued)
PTVs
% Volume covered 98.6 ± 1.2 (95.0–100.0)
(n = 64)

by RX dose (%)

PTVs

D99% (Gy)

98.1

±

1.8

(95.0–

100.0)
19.8 ± 0.18 (19.6–20.1)

19.8 ± 0.38 (19.1–
20.3)

(n = 64)
Maximum

dose 25.3 ± 1.3 (23.4–26.8)

(Gy)
Mean dose (Gy)

25.9 ± 0.77 (24.4–
27.2)

22.4 ± 0.66 (21.4–23.2)

22.8 ± 0.39 (21.9–
23.3)

CI

0.98 ± 0.01 (0.97–0.99)

0.97 ± 0.03 (0.91–
1.01)

Differences in OAR doses between the single isocenter VMAT and the dual
isocenter VMAT plans can be seen in figure 5.4. All plans were optimized based on RTOG0933 protocol for hippocampal sparing with a converted effective biological single-fraction
maximum dose of < 6.5 Gy and QUANTEC guidelines for brainstem and optics apparatus
doses of < 8 Gy and < 12 Gy, respectively. The result contains maximum doses to the
brainstem, optics apparatus and hippocampi for all patients. The maximum dose to the
brainstem for the single isocenter VMAT was 13.1 ± 7.2 Gy (2.2–21.8 Gy) and 11.9 ± 7.5
Gy (2.8–21.5 Gy) for the dual isocenter plans. In this cohort, maximum dose to the optics
apparatus was 6.0 ± 3.7 Gy (2.2–12.4 Gy) for the single isocenter plans and 4.5 ± 1.6 Gy
(2.4–7.4 Gy) for the dual isocenter plans. Similarly, the maximum dose to the hippocampi
was 10.4 ± 4.5 Gy (6.1–19.1 Gy) for the single isocenter plans and 9.3 ± 5.3 Gy (4.3–19.9
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Gy) for dual isocenter plans. The dual isocenter plans clearly resulted in sparing OAR
compared to the single isocenter VMAT plans.

Figure 5.4 Box plots of maximum dose to OAR for all 7 patients.
Box plot of maximum dose to OAR for all 7 patients. The left panel (brainstem), middle
panel (optics apparatus) and the right panel (hippocampi). The blue box plot represents the
single isocenter VMAT and the orange box plot represents the dual isocenter VMAT plan.
The black crosshair signifies the average value for each specific set. Overall, the dual
isocenter plan showed better sparing of the critical structures.
Differences in normal brain dose between the single isocenter VMAT plans and the
dual isocenter VMAT plans can be seen in figure 5.5. With the dual isocenter plans, there
was a significant reduction of V8Gy, V12Gy and MBD compared to the single isocenter
plans. Average V8Gy among all patients was 226.7 ± 135.4 cc (90.1–412.9 cc) for the
single isocenter plans and 147.2 ± 43.1 cc (86.9–209.7 cc) for the dual isocenter plans. For
all patients, V12Gy was 56.5 ± 34.8 cc (32.0–131.0 cc), on average for the single isocenter
plans and 147.3 ± 16.4 cc (32.3–81.1 cc) for the dual isocenter VMAT plans. Similarly,
MBD was reduced from 5.2 ± 1.4 Gy (4.1–7.3 Gy) to 4.2 ± 0.79 Gy (3.4–5.6 Gy) for the
dual isocenter vs dual isocenter VMAT plans.
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Figure 5.5 Box plot of dose to normal brain.
Box plot of dose to normal brain. The left panel (V8Gy), middle panel (V12Gy) and the
right panel (MBD). Blue box is the single isocenter plans and the orange is the dual
isocenter plans. The black crosshair is the average values for each parameter. The dual
isocenter plans resulted in significant decreases in V8Gy, V12Gy and MBD compared to
the single isocenter plan.
The reduction of OAR maximal doses and normal brain doses with dual isocenter
planning can be attributed to a decreased intermediate and low dose spillage as seen in
figure 5.6. Low and intermediate dose spillage is defined by V30% and V50%. For the
single isocenter plan, average V30% was 494.2 ± 242.5 cc (246.0–839.7 cc) and V50%
was 133.7 ± 75.3 cc (67.2–261.3 cc). For the dual isocenter plans, the average V30% was
333.6 ± 83.4 cc (201.9–414.9 cc) and V50% was 101.9 ± 30.8 cc (65.2–148.6 cc), reducing
intermediate dose spillage by a factor of 1.5. Island blocking in single isocenter VMAT
treatments for brain metastases is of major concern because it can cause low and
intermediate dose spillage increasing the dose to normal brain. The dual isocenter plans
could minimized this problem.
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Figure 5.6 Low and intermediate dose spill for all 7 patients.
Low and intermediate dose spillage of all 7 patients. The blue bar represents the single
isocenter VMAT plan and the red bar represents the dual isocenter VMAT plan with
standard deviation error bars. Low and intermediate dose spillage are defined by the
average V30% and V50% among all patients. Significant improvements in the low and
intermediate spillage with the dual isocenter plans compared to the single isocentr plans is
obvious.
Figure 5.7 shows the comparison of treatment delivery parameters between the
single isocenter VMAT and dual isocenter VMAT plans. The dual isocenter showed to
have a decrease in total MU and MF. The single isocenter plans had an average total MU
of 12497 ± 2925 (9277–17687) and the dual isocenter plan had 10608 ± 1856 (7790–
12468) and the corresponding average MF of 6.2 ± 1.5 (4.6–8.8) and 5.3 ± 0.93 (3.2–5.2),
respectively. The BOT was only slightly decreased for the dual isocenter plan, but the
overall treatment time increased, as expected. That is because with a dual isocenter plan,
there are 2 isocenters to setup and verification, 2 conebeam CT scans, and image alignment
that has to be done, increasing the total treatment time. The BOT and overall treatment
time for the single isocenter plan was 5.2 ± 1.2 min (3.9–7.4 min) and 20.2 ± 1.2 (1.9–22.4
min), respectively. For the dual isocenter plan, the BOT and overall treatment time were
4.4 ± 0.77 min (3.2–5.2 min) and 29.4 ± 0.77 min (28.2–30.2 min).
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Figure 5.7 Evaluation of treatment delivery parameters for all 7 patients.
Evaluation of treatment delivery parameters for all 7 patients with multiple brain
metastases (64 total lesions) for both the single isocenter plans (dark blue) and dual
isocenter plans (light blue). The dual isocenter plans resulted in slightly decreased total
MU and MF (top panel) compared to the single isocenter plans. There was also only a slight
decrease in BOT (bottom left), but an increase, as expected, in total treatment time (bottom
right). This is due to the patient setup and verification for each of the two isocenters.
5.4

Discussion
A clinically useful and patient friendly dual isocenter VMAT planning strategy has

been exhibited to minimize the effects of island blocking and improve target localization
accuracy. Additionally, this planning approach utilizes DCA based VMAT planning,
providing better plan quality while limiting brain toxicity and dose to OAR. By using two
isocenters and grouping the targets based on the brain hemisphere, a smaller number of
lesions will share the MLC pairs, limiting the bridging of low and intermediate dose spills,
further lowering doses to normal brain and adjacent OAR. This was demonstrated by lower
MBD, V8Gy and V12Gy and could potentially reduce brain necrosis.24 Superior plans can
be achieved all while maintaining optimal plan quality with fewer number of total MU and
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slightly higher doses to the GTV. This technique makes planning process simple for the
SRS planner by providing guidance on how to handle even the most complex types of
patients. The workflow for treatment by the therapists is also simplified to effortless as
described in figure 5.8. For instance, the left brain lesions are setup, imaged and treated
independently of the right brain lesions. This simplified workflow allows for each isocenter
to be set up independently on a daily conebeam CT, reducing the ROI for image matching
at the console, which would potentially reduce target localization spatial uncertainty. While
utilizing non-coplanar partial arcs in the treated side will minimize dose to the other side
of the brain. Although, a dual isocenter workflow comes with relatively longer overall
treatment times compared to that of a single isocenter treatment. However, this provides
an opportunity for the treating physician and the patients who cannot handle longer
treatment times to be treated on two different days, improving patient compliance and
potentially reducing the brain toxicity.
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Figure 5.8 Propose dual isocenter VMAT treatment delivery workflow.
The proposed dual-isocenter VMAT-SRS treatment delivery workflow for large number
of multiple brain metastases patients. The physician has the option to set up left and right
sided brain parenchyma to line up each group of the tumors one at a time, potentially
improving targeting accuracy.
As discussed previously, many researchers have worked to overcome the
challenges of target localization accuracy and minimize the island blocking that comes with
treating Linac-based SRS for patients with many lesions.18-19Efforts for mitigating this low
dose spillage has mostly been through Linac geometry optimization. 27 For example, Kang
et al. performed a computational study to develop a beam projection method to determine
suitable table and collimator angles to best minimize MLC leaf sharing between lesions.
They concluded that their optimization method minimized island blocking for their 3
example cases.26 This methodology does great work to minimize or eliminate island
blocking for patients with few lesions, but begins to fall apart for more complex patients
with a large number of tumors where eliminating shared MLC pairs is nearly impossible.
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This type of optimization is a good compliment in addition to the proposed dual isocenter
method in this study to manage the most complex of brain metastases patients and reduce
the effects of low and intermediate dose spillage due to island blocking. In addition, Chang
et al. created a DCA planning technique with a variable number of isocenters (1-3)
depending on the distribution and number of targets. They intended to use create an
approach with a shortened treatment time that still achieved the plan quality of that with
multiple targets. They concluded that their restricted isocenter method could produce
satisfactory SRS plans, but resulted in increased dose to OAR and normal brain.31 By using
exclusively DCA approaches, there is less modulation, which can lead to better target
conformity, but will not as successfully block normal tissue structures. Single isocenter
DCA approaches proved to be a solution to the long treatment times of multi-isocenter
based SRS.29 However, DCA approaches are not very suitable for flattening filter free
(FFF) beams because of their unflattened beam profiles. FFF beams provide a higher dose
rate, decrease lateral beam hardening and reduce out of field dose because of less lateral
scatter, giving them an advantage for stereotactic treatments. The novel dual isocenter
approach in this study uses a DCA-VMAT hybrid method to best reduce the effects of low
and intermediate dose spillage, perhaps reducing brain toxicity.
Though this study is a step forward for management of large number of multiple
brain metastases, it does present with some limitations. As mentioned before, compared to
a single isocenter VMAT, there is an increase in overall total treatment time due to two
separate isocenters setup and CBCT verification. Though the overall treatment time is
increased, it also opens an opportunity for the attending physician to treat lesions in halves
on two separate occasions, keeping up the clinic workflow. This opportunity is
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advantageous to the patients who struggle with longer treatment times, benefiting overall
patient compliance and potentially minimizing the brain toxicity. This study uses standard
millennium MLC (5 mm), though it is recommended to use micro MLC for Linac-based
SRS for more conformal dose distribution.32 Utilizing micro-MLCs in this dual isocenter
plan would create highly conformal dose distributions along with further reducing
intermediate dose bridging and spare adjacent OAR.

5.5

Conclusion
The results of this study clearly indicate the advantages of using the dual isocenter

VMAT approach for managing multiple brain metastases patients that can minimize low
and intermediate dose spills in the brain. With a dual isocenter method, complex patients
with many brain metastases can be treated with similar plan quality with more accurate
treatment delivery accuracy while limiting dose to normal brain and adjacent OAR and
improving patient comfort compared to multiple isocenter treatments. Incorporating dual
isocenter VMAT-SRS is recommended for managing difficult patients with large number
of brain lesions on the palliative setting.
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CHAPTER 6. PREDICTING THE EFFECT OF INDIRECT CELL KILL IN THE TREATMENT OF
MULTIPLE BRAIN METASTASES VIA SINGLE ISOCENTER/MULTI-TARGET VOLUMETRIC
MODULATED ARC THERAPY STEREOTACTIC RADIOSURGERY

With peaking interest of the fast delivery of SIMT VMAT SRS of multiple brain
lesions resulting in improved patient compliance and clinic workflow, a few clinical
outcome studies have recently shown positive results of tumor local control rates. This
positive feedback is present even with residual patient set up errors reported in Chapters 1
and 2. To further understand the results, an investigation of the radiobiological
mechanisms, such as secondary cell death as a function of patient setup error was explored.
In addition to direct cell death, indirect cell kill could have played a major role in providing
clinically acceptable outcomes in these treatment types. The results of this chapter provide
a better understanding for the importance of patient setup uncertainty when considering
secondary cell kill effects in SIMT setting. Physicians can have the opportunity to consider
these radiobiological effects, understand the limitations of patient setup errors and have
more confidence in their SIMT VMAT plans for treating complex patients with multiple
brain metastases. This chapter has been adopted by the recently revised manuscript by:
Palmiero A, Fabian D, Randall M, St. Clair W and Pokhrel D. “Predicting the Effect of
Indirect Cell Kill in the Treatment of Multiple Brain Metastases via Single
Isocenter/Multitarget Volumetric Modulated Arc Therapy Stereotactic Radiosurgery. J
Appl Clin Med Phys. (Under Review, submitted February 2021).
Abstract
Purpose: Due to spatial uncertainty, patient setup errors are of major concern for
radiosurgery of multiple brain metastases (m-bm) when using single-isocenter/multi-target
(SIMT) volumetric modulated arc therapy (VMAT) techniques. However, recent clinical
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outcome studies show high rates of tumor local control for SIMT-VMAT. In addition to
direct cell kill (DCK), another possible explanation includes the effects of indirect cell kill
(ICK) via devascularization for a single-dose of 15 Gy or more. This study quantifies the
role of indirect cell death in dosimetric errors as a function of patient setup uncertainty.
Material/Methods: Nine complex patients with 61 total tumors (2-16 tumors/patient) were
planned using SIMT-VMAT with geometry similar to HyperArc with a 10MV-FFF beam
(2400 MU/min). Isocenter was placed at the geometric center of all tumors. Average gross
tumor volume (GTV) and planning target volume (PTV) were 1.1 cc (0.02–11.5 cc) and
1.9 cc (0.11–18.8 cc) with an average distance to isocenter of 5.5 cm (1.6–10.1 cm).
Prescription was 20 Gy to each GTV. Plans were recalculated with induced clinically
observable patient setup errors [± 2 mm, ± 2o] in all 6 directions. Boolean structures were
generated to calculate the effect of DCK via 20 Gy isodose volume (IDV) and ICK via 15
Gy IDV minus the 20 Gy IDV. Contributions of each IDV to the PTV coverage were
analyzed along with normal brain toxicity due to the patient set up uncertainty. Induced
uncertainty and minimum dose covering the entire PTV were analyzed to determine the
maximum tolerable patient setup errors to utilize ICK for radiosurgery of m-bm via SIMTVMAT.
Results: Patient set up errors of 1.3 mm/1.3°in all 6 directions must be maintained in order
to achieve PTV coverage of the15 Gy IDV for ICK. Setup errors of 2 mm/2° showed
clinically unacceptable loss of PTV coverage of 29.4 ±14.6% even accounting the ICK
effect. However, no significant effect on normal brain dosimetry was observed.
Conclusion: Radiosurgery of m-bm using SIMT-VMAT treatments have shown positive
clinical outcomes even with small residual patient set up errors. These clinical outcomes,
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while largely due to DCK, may also potentially be due to ICK. Potential mechanisms, such
as devascularization, should be explored to provide a better understanding of the
radiobiology of stereotactic radiosurgery of m-bm using a SIMT-VMAT plan.

6.1

Introduction
Due to fast treatment delivery, single-isocenter/multi-target (SIMT) volumetric

modulated arc therapy (VMAT) stereotactic radiosurgery (SRS) has become an
increasingly popular treatment modality in the management of multiple brain metastases
(m-bm).1-3 Recently, this approach has been adopted and automated by Varian (Varian
Medical Systems, Palo Alto, CA) in the Eclipse treatment planning system (TPS, version
15.6) as the HyperArc module, which has generated global clinical interest.4-9 SIMTVMAT reduces treatment times while improving patient comfort and clinic workflow;
however, there are concerns with patient set up uncertainty when treating multiple targets
simultaneously. It has been previously demonstrated that clinically unacceptable
dosimetric discrepancies due to rotational set up errors were present compared to treating
each lesion individually.10-19 The most recent simulation study demonstrated that there was
a large loss of target(s) coverage, (30% average, but up to 70% for small lesions) due to
both rotational and translational set up errors while using SIMT-VMAT SRS for m-bm.20
This is a challenge in lining up all tumors correctly using a single daily conebeam CT,
especially since skull-based rigid alignment is required. In addition, visibility is low inside
the brain on low quality CBCT. Targets may slightly move if there is intracranial edema.
Nevertheless, a recent clinical study by Palmer et al. demonstrated positive outcomes of
SIMT treatments.21 They reviewed 173 patients treated with 1 to 5 brain lesions that
underwent single-isocenter SRS treatments. After an average of 12 months following up,
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very promising 1 year and 2 year tumor local-control rates of 99% and 95% was observed.
Other clinical studies have observed similar patient outcomes demonstrating SIMT-VMAT
SRS for m-bm to be both safe and effective with high rates of tumor response.22-25
However, the presence of positive clinical outcomes cannot be fully explained
knowing the effects of patient positioning uncertainties in SIMT-VMAT treatments.
Biological modeling, specifically with the linear-quadratic (LQ) model, overestimates
tumor control rate with SRS techniques due to the LQ cell survival curve bends
continuously downward with increases in radiation dose due to quadratic component in the
model.26 This suggests that mechanisms in addition to tumor DNA double strand breaks
and/or chromosomal aberrations must be involved. It is hypothesized that in addition to
direct cell kill (DCK), the effect of indirect cell kills (ICK) could be playing a major role
in SRS treatments. There are three types of indirect cell death to consider: strand breaks by
free radicals, antitumor immunologic rejection, and devascularization.27 A majority of
literature suggests that cell death happened soon after irradiation, pointing toward
devascularization as the mode of ICK.26-29 For instance, Song et al. performed a study to
connect the effects of radiobiological response on SBRT and SRS treatments.29 They
concluded that irradiation of tumors with doses higher than 15 Gy per fraction causes major
vascular damage accompanied by deterioration of intratumor microenvironment resulting
in secondary tumor cell death. Other studies had comparable findings.30-33 Tumor
vasculature is disorganized with weak and fragile cellular walls. Subjecting tumor vascular
to radiation damage when exposed to a single high-dose (15 Gy or higher) results in the
inverted “hockey-stick” phenomena.32 With this theoretical phenomenon, the bend of the
cell survival curve increases, where cell death is increasing at higher doses of radiation.
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When considering the effects of ICK, the local tumor control rates with the presence of
dosimetric discrepancies due to patient setup errors in SIMT-VMAT treatments has yet to
be explored.
Therefore, to provide dosimetric support for the potential contribution of secondary
cell death in the treatment of m-bm with SIMT-VMAT, a model has been created to define
the relationship between spatial uncertainty and the delivered dose. Given the previous
studies suggesting high levels of vascular damage at 15 Gy, the 15 Gy isodose volume
(IDV) around the tumor was chosen as a threshold dose that best utilizes the effects of ICK
in addition to DCK. As long as the target receives a minimum dose of 15 Gy or higher,
vascular damage could theoretically influence indirect tumor cell death. This study
attempts to characterize the patient set up errors that should be maintained in the treatment
of m-bm via SIMT-VMAT to account for both effects of direct and indirect cell kill.
Therefore, the relationship between indirect cell kill and patient setup errors was used to
define an uncertainty cutoff. This model can give suggestions for limits on patient setup
uncertainty that physicians can consider, giving them confidence in their SIMT-VMAT
plans for treating multiple brain metastases.

6.2
6.2.1

Materials and Methods
Patient information
Nine complex patients with 2-16 (61 total) brain metastases (all lung primary) were

included in this study approved by our institutional review board. These patients were
previously treated through single fraction SRS. High resolution double contrast MPRAGE
MRI images (Siemens MAGNETOM, 1.5T MRI System, Ferndale, MI) were used for
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tumor and organs at risk (OAR) delineation and were co-registered to planning CT images
in the Varian Eclipse TPS. The MPRAGE MRI images were 512 × 512 pixels with 1 mm
slice thickness and no gap in between slices. The target volumes were delineated by a
radiation oncologist on the MRI with the gross tumor volumes (GTVs) defined by the
visible tumor. The planning target volumes (PTVs) were created using a uniform 1.0 mm
margin around each GTV using departmental SRS protocol. The tumor characteristics are
summarized in Table 6.1. The normal brain was considered all tissue with the GTVs
included. Additionally, nearby OAR (hippocampi, brainstem and optics apparatus) were
contoured for dose reporting. Distance to isocenter was calculated as the 3D Euclidian
distance from the isocenter and the lesion. The average distance to isocenter was 5.5 cm
(range: 1.6–10.2 cm) as shown in table 6.1.
Table 6.1 Tumor characteristics of the patients included in the study
Patient No. of
Avg.
Total
Total PTV
Adjacent OAR
no.

lesions

distance to

GTV

isocenter

(cc)

(cc)

(cm)
I

2

2.2

2.2 ±

3.7 ± 1.1

Hippocampi

0.93 ± 0.78

Hippocampi

0.78
II

3

5.7

0.43 ±
0.78

III

4

6.5

3.9 ± 5.2

6.5 ± 8.3

Hippocampi, Optics

IV

5

8.9

3.3 ± 3.3

4.9 ± 4.3

Hippocampi

V

6

5.4

1.3 ±

2.1 ± 1.1

Hippocampi

0.72
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Table 6.1 (Continued)
VI
7

5.0

0.75 ±

1.4 ± 1.2

0.81
VII

8

4.3

0.51 ±

Brainstem,
Hippocampi

1.0 ± 0.93

Brainstem, Hippocampi

0.86 ± 0.46

Hippocampi

0.83 ± 1.0

Optic apparatus,

0.58
VIII

10

5.5

0.39 ±
0.46

IX

16

5.4

0.43 ±
0.63

6.2.2

Hippocampi, Brainstem

SIMT-VMAT plans
SIMT-VMAT SRS plans were generated in the Eclipse TPS for the TrueBeam

LINAC (Varian Medical Systems, Palo Alto, CA) with a 10 MV flattening filter free (FFF)
beam (2400 MU/min). A HyperArc style, fixed-geometry was mimicked with 3
noncoplanar partial arcs and one full arc with couch positions at 0o, 45o, 315o, and 270o.
The isocenter position was chosen at the approximate geometric center of all targets.
Patient specific collimator angles were manually assigned to best minimize island blocking
and dose spill outside of the target(s). The prescription was 20 Gy to each lesion to the 7080% isodose line and optimized so that 95% of the target volume receives 100% of the
prescription dose. The dose was calculated using Anisotropic Analytic Algorithm (AAA)
(Eclipse, version 15.5) with the smallest calculation grid size of 1.25 mm. Ring structures
to each target, jaw tracking and normal tissue objective were used during inverse
optimization for dose steering and to maintain dose fall-off outside the target(s).
Hippocampi were spared following RTOG-0933 along with the optics apparatus and
brainstem meeting QUANTEC guidelines.34-36
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6.2.3

Simulated SIMT-VMAT plans
Clinically observable patient setup uncertainties of ±0.5 mm/0.5°, ±1 mm/1° and

±2 mm/2° in all 6 degrees-of- freedom (6DOF) were systematically simulated by using an
in-house registration method. Rotational errors were defined as the pitch (y-z plane), roll
(x-z plane) and yaw (x-y plane) relative to the isocenter position. After the SIMT-VMAT
plans were generated, the image set was duplicated and re-registered to the original MRI
images. This registration was exported from the Eclipse TPS as a DICOM file and imported
into a MATLAB script (Mathworks Inc., WA, USA). The script generated a matrix with
rotational (Δα, Δβ, Δγ) and translational (Δx, Δy, Δz) values and was applied to the
reference frame. A new image registration DICOM file was generated and then imported
back into the Eclipse TPS with a new transformation matrix applied. The original plan was
then overlaid on to the new transformation and the dose was recalculated with the only
difference being the isocenter shift.
6.2.4

Modeling direct vs. indirect cell kill
This work attempts to model the effects of cell killing due to both direct and indirect

cell kill methods. An assumption is made that for areas of the target receiving the
prescription dose, 20 Gy or higher, tumor death is due to primarily direct cell killing
methods, or DNA double strand breaks. Alternatively, for areas of the target receiving 15
Gy or higher, it is hypothesized that the tumor cell death is largely due to ICK method via
devascularization of the tumor and deteriorating the intratumor microenvironment. This
threshold for ICK comes from the literature, as mentioned previously. Doses above 15 Gy
could result in vasculature damage and, therefore, indirectly killing the tumor.26-33 These
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assumptions are made to simplify the model, though, realistically, combinations of both
direct and indirect cell kill are present.
Both DCK and ICK methods were modeled using Boolean operators in the
contouring module of the Eclipse TPS. For each PTV, the 20 Gy and 15 Gy IDV were
exported from the original SIMT-VMAT plan and each of the simulated plan for the
corresponding set up errors. Boolean operators were used to determine the overlap of the
20 Gy IDV and each PTV. This volume was denoted as the volume of the PTV receiving
DCK. Another Boolean operator was used to find the overlap of the 15 Gy IDV and each
PTV minus the 20 Gy IDV overlap with the target. This volume was signified as the volume
of the tumor that was receiving primarily ICK effects. The concepts are further illustrated
in figure 6/1. This is an example patient with 16 lesions. The orange contour is the PTVs,
the green isodose line is the prescription dose (20 Gy) and the yellow isodose line is the 15
Gy. For the original plan, the PTV is well covered by the prescription dose, therefore should
receive the greatest effects of DCK. However, the simulated plan with the set-up errors of
1 mm and 1° shows slight deviation of the 20 Gy isodose line, but the tumor is still covered
entirely by the 15 Gy line (see figure 6.1). This should result in a combination of both direct
and indirect cell kill in this patient’s treatment, which could result in positive local tumor
control rate. Furthermore, the simulated plan with 2 mm/ 2° set up errors has shown the
significant loss of target coverage by the 20 Gy isodose line, but still displays a majority
of the PTV coverage by the 15 Gy isodose line. With these large set up errors, the lesions
will have a decreased target coverage, therefore lower rate of tumor local control, even
when considering the effects of ICK.
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Figure 6.1 Example patient with 16 lesions.
Example patient’s SIMT-VMAT plan with 16 lesions and a prescription of 20 Gy to each
lesion. The left panel shows the original plan with no induced setup uncertainties, the
middle panel shows a simulated plan with 1 mm/ 1° setup errors and the right panel shows
another simulated plan with 2 mm/ 2° setup uncertainty in all 6 DOF. The orange contour
is the PTV(s), the green isodose line is the prescription dose (20 Gy) and the yellow isodose
line is 15 Gy. The simulation plans show decreasingly less coverage by the 20 Gy isodose
line compared to the original plan, demonstrating the dosimetric effects of set up errors and
the contribution of ICK.
6.2.5

Data Analysis
None of these SRS patients were treated with the SIMT-VMAT plans. This

simulation study sought to find the maximum tolerable set up errors to fully utilize the
effects of both direct and indirect cell kill to achieve acceptable local tumor control in the
SIMT setting. Boolean structures of IDV were created iteratively until a dose was found to
just fully cover the target. This process was repeated for the original SIMT-VMAT plans
and each of the corresponding simulated VMAT plan. Doses found to cover the target with
15 Gy IDV and above were deemed acceptable and assumed to generate positive local
tumor control rate via ICK. The roles of direct vs. indirect cell killing were also compared
for each tumor. These were defined by creating Boolean structures for both the 15 Gy and
20 Gy IDV as further described in the previous section. The volumes of these structures
were taken and compared as a percentage of the PTV volume receiving that dose. These
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values were compared for the original SIMT-VMAT plans and each of the corresponding
simulated VMAT plans with the clinically realistic setup errors.
It is also of clinical interest to compare the effect that patient setup uncertainties have
on normal brain dose and the role it could play in radionecrosis. For this reason, the normal
tissue (brain) complication probability (NTCP) was modeled based on a study by Milano
et al.37 This group pooled published reports of clinical data of radiation induced brain
toxicity after receiving brain SRS treatments (single and multiple fractions). The data was
fitted and a logistic model was used to create a usable NTCP function given by the
following relation:
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 =

1
𝑉𝑉
1 + ( 𝑥𝑥50 )4𝛾𝛾50
𝑉𝑉𝑉𝑉

Where, 𝑉𝑉𝑉𝑉 is considered the volume receiving greater than or equal to a dose of 𝑥𝑥 Gy

and 𝑉𝑉𝑥𝑥50 is the volume corresponding to 50% risk of radionecrosis with 𝛾𝛾50 as a slope

parameter. The values of 𝑉𝑉𝑥𝑥50 and 𝛾𝛾50 were taken from their NTCP model for brain

metastases.37 In addition to doses to normal brain, changes in the maximum dose to OAR
due to setup errors were also reported.

6.3

Results
Figure 6.2 demonstrates the setup uncertainty limitations for the target (PTV) to be

fully covered by at least 15 Gy or higher and, therefore, best utilize the effects of ICK in
addition to DCK. The dose covering the target was taken for the original SIMT-VMAT
plans and all the corresponding simulated VMAT plans. The original SIMT-VMAT plans
were found to be fully covered the target by an average of 19.2 ± 0.3 Gy. As expected, the
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corresponding simulated plans with an induced setup errors of 0.5 mm/ 0.5°, 1 mm/ 1° and
2 mm/ 2° were found to have the corresponding lower doses by 17.8 ± 0.8 Gy, 15.9 ± 0.9
Gy and 12.6 ± 1.5 Gy, respectively. This data was evaluated with a threshold of ICK by 15
Gy or higher in figure 6.2. To fully utilize indirect cell killing methods, patient set up errors
of at least 1.3 mm/1.3° in all 6 DOF must be maintained as shown by the background
change of blue to red. Above this threshold of 1.3 mm/1.3° in all 6DOF, indirect cell kill
could potentially contribute to the tumor cells death.

Figure 6.2 Illustration of dose to targets for original and simulated VMAT plans
Illustration of the dose to target(s) for the original SIMT-VMAT plans and the
corresponding simulated VMAT plans with 0.5 mm/ 0.5°, 1 mm/ 1° and 2 mm/ 2° setup
errors. The blue line represents the dose that fully covers the target and the dotted red line
represents the 15 Gy ICK threshold. The section of the plot covered in blue represents the
target(s) coverage that is above the 15 Gy threshold, and the orange is below 15 Gy. Patient
set up errors must be limited to those defined by the blue area.
The contributions of the direct vs indirect cell kill methods are explained in figure
6.3. The Boolean structure of the 20 Gy IDV and PTV is considered primarily DCK
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contributions, whereas the Boolean structure of the 15 Gy IDV and PTV minus the 20 Gy
IDV is considered contributions from primarily ICK. For the original plans, the PTV was
covered almost completely by the 20 Gy IDV for 97.97 ± 3.52 % and no coverage by the
15 Gy IDV. For the corresponding simulated VMAT plans of 0.5 mm/ 0.5°, 1 mm/ 1° and
2 mm/ 2° of setup errors the 20 Gy IDV coverage was 80.0 ± 28.5%, 67.9 ± 21.6% and
47.6 ± 23.6% and the 15 Gy IDV coverage was 4.2 ± 13.1%, 15.4 ± 10.8% and 29.4 ±
14.6%, respectively. The contribution of DCK decreases as that of ICK increases, with 2
mm/ 2° having the worst overall target coverage, but most importantly adding some ICK
contributions. The DCK is somehow compensating for much of the dosimetric discrepancy
up to 1.0 mm/1.0°. There is acceptable target coverage (> 15 Gy), providing a better
combined coverage, and therefore potentially positive outcomes.

Figure 6.3 Illustration of the target coverage by direct and indirect cell kill.
Illustration of the target coverage by the 15 Gy and 20 Gy isodose lines. The blue represents
the coverage obtained by 20 Gy isodose line, which is assumed to be primarily responsible
for DCK. The red represents the 15 Gy isodose line or more, which is assumed to be
primarily inducing ICK in addition to DCK. Without considering setup uncertainty, the
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target is nearly fully covered by the prescription isodose line (20 Gy) and could receive full
effects of DCK. With induced setup errors, the coverage of the target by the prescription
decreases, but is somewhat counterbalanced by the effects of ICK by 15 Gy or higher.
It has been observed that patient misalignment errors have minimal or no effect on
NTCP of brain as shown in figure 6.4. For each of the patients, the NTCP was calculated
and compared with the whole brain receiving V14 Gy. For a majority of patients, there is
not much of an increase in values of NTCP with any setup uncertainties up to 2 mm and
2°. For instance, the increase of NTCP of normal brain toxicity at set up errors of 2 mm
and 2°in each direction had an absolute difference of < 0.4 compared to the original plan
with no set up errors, suggesting minimal brain toxicity risk while still resulting in clinical
local tumor control. Based on percent differences in NTCP, it was determined that brain
toxicity was 1.3%, 1.5% and 1.7% more likely for 0.5 mm/ 0.5°, 1 mm/ 1° and 2 mm/ 2°
simulated plans. However, it is apparent that NTCP does increase with whole brain
V14Gy, but the increase due to setup errors is not clinically significant for lower brain V14
Gy (see figure 6.4).
The dose to OAR fluctuated depending on the distribution and orientation of the
lesions to the immediately adjacent organs. Many cases resulted in substantial increases in
dose to OAR with increased dose to hippocampi, brainstem and optic apparatus up to 3 Gy,
2 Gy and 1 Gy, respectively, due to patient set up errors using SIMT-VMAT.
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Figure 6.4 Comparison of NTCP with brain V14 for all plans
Comparison of NTCP of whole brain V14Gy for original SIMT-VMAT plans and the
corresponding simulated VMAT plans with induced setup uncertainties of 0.5 mm/ 0.5°, 1
mm/ 1° and 2 mm/ 2° in all 6DOF. Values of Vx50 and γ50 were obtained from literature
as 45.8 cc and 0.88, respectively. 37 The blue points represent NTCP with no setup
uncertainty, the red ±0.5 mm/ 0.5°, the purple ±1 mm/ 1 and the green ±2 mm/ 2° as a
function whole brain V14Gy. There is no clinically significant increase in NTCP due to
patient set up errors, however NTCP of normal brain increases significantly as a function
of V14Gy for those patients with increasing V14Gy above 30 cc.
6.4

Discussion
In addition to DCK, the effects of ICK responsible for providing better local tumor

control rates for SIMT-VMAT plan are explored with consideration of dosimetric
discrepancies due to patient setup errors. This model determines the setup uncertainty
limits for physicians that fully utilizes ICK to maintain acceptable tumor coverage. This
was done by determining the dose levels that fully cover the target for SIMT-VMAT plans
with no setup uncertainty compared to clinically observable patient set up errors of 0.5
mm/ 0.5°, 1 mm/ 1° and 2 mm/ 2° in all 6 DOF. Setup limits of at least 1.3 mm and 1.3° or
better in all 6DOF was found as the threshold to maintain acceptable target dose while
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including the effects of ICK. The amount of contribution of both direct and indirect cell
kill was also modeled using Boolean structures, so that 20 Gy IDV was assumed to be
primarily responsible for DCK, while the 15 Gy to 20 Gy IDV was assumed to be primarily
contributing due to ICK. As set up uncertainty increases, the contribution of ICK increases
and, therefore, tumor cell death by devascularization. The apparent dosimetric disparity
from losing target coverage of the prescription dose is partially mitigated by incorporating
the concept of secondary cell kill. In addition, the effects of setup uncertainty on the normal
brain were modeled using NTCP. No clinically significant increase of NTCP of the brain
due to set up errors was observed, while clinically significant increases in OAR are possible
for these set up uncertainties due to the proximity of the organs.
Treating m-bm with a single-isocenter plan comes with many challenges including
dosimetric disparities due to patient positioning errors.14-20 This presents concerns in terms
of local tumor control and unexpected dosing to the normal brain and other adjacent critical
structures in the brain. The QUANTEC guidelines for normal brain tissue cite a study
relating V12Gy to radiation induced necrosis, where the risk of NTCP increases from 23%
for V12Gy between 0 and 5 cc and 54% for V12Gy at 10 to 15 cc.38-39 It should be noted
that dose to whole brain to a certain dose level is primarily on treated volume rather than
number, shape, or location of lesions.40 Several clinical outcome studies have reported
positive results of higher tumor local control rates of SIMT-VMAT treatment that do not
align with the presence of these dosimetric disparities.21-25 For instance Alongi et al. used
Varian single-isocenter VMAT in the treatment of 43 patients with m-bm and performed a
clinical follow up study within 6 months. They observed that 60% of the patients with
partial or complete responses and 40% with stable disease control, though the medial
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overall survival had not yet been reported.22 Other studies have found similar tumor local
control rates for linac based brain SRS using single-isocenter plans.21,23-24 These clinical
observations lead to the consideration of how the radiobiology of single fraction, high dose
SRS could play an important role in SIMT-VMAT for treating m-bm.
Recently, Sperduto et al. discussed the high control rates of stereotactic body
radiation therapy (SBRT) and SRS and suggested the concept of ICK.32 They discuss the
roles biological models play in the evaluation of outcomes in SRS treatments. Their results
suggest that a single dose of 15 Gy or higher correlates with indirect death of hypoxic cells
by modes of devascularization and potentially radiation induced immune enhancement.
The authors conclude that in addition to DCK, the secondary cell death by modes of
devascularization may be the mechanism of interest that providing success for SRS/SBRT.
This must be considered when evaluating dosimetric uncertainties due to set up errors for
SIMT-VMAT treatments. Both direct and indirect cell kill could be playing roles in tumor
cells death, resulting in the higher local control rates reported by the mentioned clinical
observations. This simulation study demonstrated that acceptable target dose could be
maintained when small setup uncertainties exist because the target coverage by a dose of
15 Gy or higher is still maintained and there for cell death by devascularization. It is
therefore suggested that if setup errors cannot be maintained between 1.3 mm/1.3° in all 6
DOF, alternative treatment methods to m-bm should be used. It is recommended to use
either a dual-isocenter approach or traditional individual isocenter to each tumor methods
instead.41
Though this study brings perspective to radiobiological effects that exist when
treating m-bm via SIMT-VMAT plan, some limitations must be considered. Though
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positive outcomes were evident, there were still discrepancies between the literature for
local controle rates. This study is describing single fraction treatments, while the literature
supporting positive local control range from single to 5 fractions with a variable number
of patients receiving WBRT or surgical resection in addition to SRS treatments. They also
use larger margins of 2-3 mm, which could be accounting for some levels of uncertainty,
though the effect on normal brain is not mentioned.21-22 These high local control rates are
still useful in describing the indirect cell kill effects that could be taking place with high
dose per fraction treatments, even with patient setup errors, although cannot be predictive
for all patient cohorts. As mentioned previously, an assumption is made in this study that
the 15 Gy or higher IDV is a parameter of choice to describe the effect of ICK. However,
there are some studies suggesting a single dose of 10-12 Gy as a threshold for ICK.28-30
Moreover, it is actually a combination of both indirect and direct killing methods that take
place between 15 Gy and 20 Gy, though for simplification, just ICK is considered. This
study is also limited by the TPS resolution limits when considering the tumor size of this
patient cohort. These in combination will cause rounding of IDV and Boolean structures,
meaning some results for very small tumors will not be as accurate as those of larger
tumors. Lastly, the LQ model is not an adequate representation of a dose response
relationship for single fraction SRS treatments, and though work has been done to create a
relevant model, there is not currently a definite solution.42 Though 15 Gy is a potential
parameter to consider, it may be difficult to directly apply this value. The studies mentioned
were done with human fibrosarcoma xenografts that grew in the legs of mice up to 6-7 mm
in diameter and irradiated with single fractions, where some brain mets are larger in size.2531

Therefore, it must be recognized that this is a simulation study, therefore the results
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reported are not predictive of current patient treatment. Further clinical studies are
warranted.
However, future research includes incorporating this ICK approach for SIMTVMAT plans in the treatment of m-bm for reporting and clinical follow up of the patient’s
tumor local control and treatment related toxicity. It is also important to further investigate
the radiobiological models of single fraction SRS treatments in terms of tumor control
probability (TCP) and how residual patient setup errors could affect the predicted treatment
outcomes. Efforts have been made to model the TCP for single fraction treatments, but
many still present with problems associated with unreliability of the LQ model that was
historically generated for fractionated radiotherapy.43 Therefore, TCP depends on clinical
observations rather than predicting local control rates. It will also be useful to use cellular
modeling to further understand the magnitude of the damage made by DCK vs. ICK with
respect to reduced tumor cell kill for some given dose levels as seen by tumor recurrences.

6.5

Conclusion
SRS treatment of m-bm using a SIMT-VMAT plan will result in dosimetric

discrepancies due to immitigable residual patient positioning uncertainties. In addition to
DCK, vascular damage as a form of ICK due to single-dose of 15 Gy or higher could
potentially compensate for these dosimetric errors and still presenting positive outcomes
for the tumor local control along with no significant increases in normal brain toxicity.
Clinical follow up results of the m-bm patients treated via a SIMT-VMAT SRS plan that
incorporates ICK in addition to DCK is warranted.
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CHAPTER 7. SUMMARY AND CONCLUSIONS
7.1

Study Summary
This dissertation has described the development and clinical exploration of

stereotactic radiosurgery to treat multiple brain metastases efficiently and accurately using
a single isocenter VMAT. Chapter 1 of this dissertation gave a brief overview of how
brain metastases are diagnosed and a discussion of treatment options with clinical
limitations. Chapter 1 then concluded with an outline of the dissertation and the clinical
innovations of each aim of the study. It outlines the overall clinical rationale and purpose
to further develop single isocenter VMAT techniques to further develop SIMT-VMAT to
be a more accurate and efficient treatment modality.
Chapter 2 presented a study that investigates the effect rotational and translational
patient set up errors have on target coverage and dose to OAR. SIMT VMAT is an efficient
form of SRS to multiple brain metastases. However, in current clinical practice, this
treatment technique does not account for residual patient setup uncertainty, which would
degrade treatment delivery accuracy. In the study presented in Chapter 2, loss of target
coverage is quantified along with the potential collateral damage to adjacent normal tissue
(including normal brain) due to isocenter misalignment. During single isocenter VMAT
planning, the isocenter was placed at the geometric center of all the tumors. A MATLAB
script was developed and used to induce clinically realistic, random setup uncertainties in
all 6 DOF. This script used image registration files to shift the isocenter with the clinically
observable patient setup shifts, inducing translational and rotational errors on the original
planning images. The dose was then recalculated on the rotated and translated images and
the new target coverage and dose to nearby critical structures was compared to that of the
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original, unshifted plan. It was hypothesized that small setup uncertainties would lead to a
large, clinically unacceptable, loss of target coverage in this setting. The loss of target
coverage was found to be 22% on average with losses up to 94% with severity increasing
for smaller tumor volumes. However, in these complex clinical cases the clear relationship
for loss of target coverage as a function of distance to isocenter could not be concluded,
suggesting that there could be other multiple factors (such as slight change in source to
surface distance (SSD), or steep dose gradients) contributing the loss of target coverage as
well.
Chapter 3 describes and compares a novel DCA-based VMAT planning approach
with a standard single isocenter VMAT for SRS of multiple brain lesions. For small brain
lesions, in addition to patient set up uncertainty, the small field dosimetry errors are a major
concern when using small beamlets in the delivery of highly modulated single isocenter
VMAT plans. Chapter 3 investigates new planning features in order to provide the highest
quality plan and the most efficient and accurate treatment delivery. The study in this
chapter evaluates a new MLC aperture controller feature in the Varian Eclipse TPS. SIMT
VMAT plans were re-optimized using DCA-based VMAT planning approach with
identical beam geometry, dose calculation algorithm, dose calculation grid size, planning
objectives and parameters. The DCA-VMAT plans utilized a DCA base dose with high
strength field aperture shaper control priority before VMAT optimization. It was
hypothesized that less beam modulation through multiple targets would be expected. DCAVMAT plans resulted in similar tumor dose, target coverage and conformity with lower
dose to normal brain and other adjacent OAR. It also had a lower number of monitor units
and less beam modulation, resulting in a significantly reduced treatment time with higher
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QA pass rates. This approach provided excellent plan quality and also minimized small
field dosimetry errors, suggesting that incorporating DCA-based VMAT optimization for
multiple brain lesions in single isocenter VMAT approach, similar to HyperArc VMAT
module merits future investigation.
In effort to create a more accurate treatment technique when using single isocenter
VMAT, a risk adapted approach was presented in Chapter 4. Thus far, this issue has been
addressed by adding an additional margin around the tumors, providing added risk by
increasing the dose to OAR and the normal brain tissue. The risk adapted approach is an
alternative treatment planning approach that escalates dose to tumors away from isocenter,
compensating for residual setup errors. In the original single isocenter VMAT plans, 20
Gy was prescribed to each lesion. These plans were replanned using the risk adapted
approach utilizing 3 different potential prescriptions based on distance to isocenter, tumor
size and proximity to the OAR. Where tumors at a greater distance to isocenter prone to
uncertainty have an escalated prescription dose of 24 Gy; whereas larger targets in close
proximity to OAR have a decreased prescription of 18 Gy. With this technique, the
hypothesis is the lesions at a large distance from the isocenter could still receive a nominal
dose of 20 Gy to each lesion with an escalated prescription. These plans also provided less
spread of intermediate dose to the normal brain with similar treatment delivery parameters.
The risk adapted SIMT VMAT plan demonstrated promising plan quality and treatment
delivery accuracy for uncertainties up to ±1o/1 mm for patients with multiple brain lesions.
Another novel technique was introduced in Chapter 5 to manage the complexity
of treating large number of brain metastases. With a large number of lesions and a single
isocenter VMAT plan, it is unavoidable for some lesions to share the same MLC pair during
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delivery. This is known as island blocking, causing higher volume of low and intermediate
dose spill in the brain and an increased dose to OAR. The study in Chapter 5 proposed a
dual isocenter VMAT planning strategy that groups lesions based on hemisphere location
in the brain tissue, potentially providing less distance for MLC travel and reducing the
effect of island blocking, which then minimizes dose spill and improves overall plan
quality. This technique simplifies planning while increasing patient compliance by
allowing for the large number of lesions to be treated in groups. For the SIMT VMAT plan,
the isocenter was placed in the geometric center of all tumors, just as mentioned in previous
chapters. These patients were replanned with the dual isocenter approach where two
separate plans were generated with each isocenter at the geometric center of each group of
lesions. The dual isocenter VMAT plans had similar target coverage and dose conformity
with less spread of intermediate dose to the normal brain and reduced dose to OAR. It is a
simplified planning approach that comes with a tradeoff of slightly increased overall
treatment time, though it is still less than treatment times of GK SRS and traditional
multiple isocenters techniques (1 isocenter per target). Dual isocenter VMAT has potential
to improve targeting accuracy by limiting the region of interest necessary for localization.
Rather than matching the entire patient’s skull on a daily CBCT image and applying shifts,
half of the skull is matched on either side of the brain by reducing the region of interest on
the daily CBCT scan. This method is recommended for managing difficult patients with a
large number of multiple brain lesions in a palliative setting.
Due to spatial uncertainty, patient setup errors are of major concern for radiosurgery
of multiple brain metastases when using a single isocenter VMAT, as discussed in Chapter
2. However, recent clinical outcome studies showed high rates of tumor local control for
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multiple brain metastases using a single isocenter treatments.1, 2 These promising clinical
outcomes cannot be fully explained when considering patient positioning uncertainties
discussed in Chapters 1 and 2. Radiobiological response with the LQ model overestimates
the tumor control rates with SRS treatments as the survival curve bends downward with
increasing dose due to increased contribution of the quadratic component of the model. 3, 4
It is hypothesized that in addition to direct cell kill, indirect cell killing could be playing a
role in SIMT VMAT SRS, specifically devascularization of the weak, fragile intratumor
microenvironment. Recent literature suggests that tumors with doses higher than 15 Gy per
fraction cause major vascular damage resulting in secondary cell death.4 Chapter 6 works
to further quantify the role of secondary cells death in the treatment of multiple brain
metastases using single isocenter VMAT. Contributions of both direct cell kill (20 Gy
prescription isodose volume) and indirect cell kill (15 Gy minus 20 Gy isodose volume)
were investigated. Minimum dose covering the entire tumor was analyzed to determine the
maximum tolerable patient setup errors to utilize the potential radiobiologic effect of
indirect cell kill. It was found that patient setup errors of ±1.3 mm/1.3°in all 6 directions
must be maintained to achieve the acceptable target coverage of the 15 Gy isodose volume
or higher to account for the effect of indirect cell death. Setup errors above this threshold
showed unacceptable loss of target coverage, even when considering indirect cell kill,
although no significant changes in normal brain dose was observed. Positive clinical
outcomes for single isocenter VMAT could be largely due to the effect of secondary cells
death via devascularization, providing a better understanding of the radiobiological
response of SRS of multiple brain metastases in this setting.
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7.2

Study Limitations
This study aimed to ensure SIMT VMAT to be a safe, effective and accurate

treatment modality for multiple brain lesions. Though great improvements were made,
there are still some limitations that must be mentioned. The patient number among every
study performed in this dissertation was limited. The patient number used was based on
the availability of the patient data at the University of Kentucky Medical Center. This lack
of data likely impacted the statistical analysis of these studies and larger studies with a
larger patient cohort is warranted. Many of the patient images were taken from those with
previous GK radiosurgery treatments. That means the patient images were using high
resolution MRI images; therefore, for some patients, we did not have appropriate planning
CT imaging for heterogeneity corrections. For these patients, a homogeneous dose
distribution to the brain was calculated by assigning a CT value equal to water to the brain.
However, Pokhrel et al. performed a Monte Carlo study with homogenous pencil beam
algorithms concluding that only less than 2% discrepancy within the brain dose distribution
was found even with the cavernous sinus tumors.5 We do acknowledge that there might be
slight dosimetric errors by not accounting for heterogeneities in the brain, specifically the
skin dose. However, in the future, heterogenous dose distribution will be calculated on the
planning CT images (co-registering high-resolution MRI for tumor and OAR delineation)
for actual patient’s treatment via single isocenter VMAT plan.
Another caveat is all treatment planning in this dissertation was done with standard
MLC with 5 mm width due to availability at the University of Kentucky Medical Center.
The manufacture suggests that single isocenter VMAT for multiple brain lesions be limited
to linear accelerators utilizing 2.5 mm high definition MLC. However, a study from Duke
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University Medical Center demonstrated that for radiosurgery of multiple brain metastases
using single isocenter VMAT plans, 5 mm MLC can produce similar target conformity
with slightly increased 30-50% dose spillage, but can be minimized by adding more VMAT
arcs.6 We acknowledge that, by incorporating micro-MLC in the planning methods
suggested in this dissertation, even higher quality SRS treatment plans can be generated.
In Chapter 2, was hypothesized that the loss of target coverage would increase
with distance from isocenter as well as for small tumor sizes. Loss of target coverage as
function of rotational patient’s set up errors were studied by a few investigators.7-9 For
instance, Roper et al. performed a dosimetric study by systematically inducing rotational
errors of 0.5o, 1.0o, and 2.0o using Velocity AI (Velocity Medical, Atlanta GA) for patients
with 2 lesions, showing a linear relationship between diminishing PTV coverage and
distance to isocenter.7 This linear relationship was not evident in this dissertation for the
complex patient cohort with large numbers of brain lesions with some of irregular shape.
There are several other factors that could have contributed to this result. In addition to the
steep dose gradient, the small translations and rotational errors lead to changes in SSD
affecting in dose calculation algorithm resulting different dose distribution when it is
recalculated. Finally, the complexities of the many body problem presented here must be
considered, with a larger number of lesions with irregular tumor shapes, the complication
of the problem increases and might deviate the expected results based on a simple geometry
with two spherical lesions demonstrated by Roper et al.7 Compared to the above mentioned
studies, who used third party dose calculation algorithms, our dose recalculation in the
same planning system with identical algorithm (only accounting for the residual patient
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setup errors) would be accurate representation of a real time clinical scenarios. Although,
future investigation of this trend is required.
In Chapter 6, the radiobiological responses of single isocenter VMAT treatment
to multiple brain lesions was investigated as a function of residual patient setup uncertainty.
It must be noted that the LQ model begins to break down when used for single fraction
treatments, although it is controversial.10 It has been questioned whether the LQ model is
applicable to a single high dose treatment. The LQ model assumes that radiation damage
and cellular death is to DNA double strand breaks only.10 Other mechanism of cells death,
as mentioned in Chapter 6, such as devascularization could causing a delayed tumor cells
death. The LQ model is not an adequate representation of a dose response relationship for
single fraction treatments, though it is still a trusted and useful model for fractionated SRS
treatments. Though some work has been done to create a better model by accounting
secondary cells death, there is not currently a definite solution in this regard and is an active
area of ongoing research.3,4,11 It must then be recognized that the work in Chapter 6 is a
retrospective simulation study and the results reported is not predictive of current patients’
treatment.
Clinically promising tumor local control rates for SRS of multiple brain lesions
using a single isocenter treatments were reported in recent literatures as discussed in
Chapter 6. Though positive outcomes were evident, there were still discrepancies between
the literature for local control rates. This dissertation is describing single fraction
treatments, while the literature supporting positive local control was achieved from single
fraction to 5 fraction treatments with a variable number of patients receiving WBRT or
surgical resection in addition to single and multiple isocenter SRS treatments.1,2 These high
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local control rates are still useful in describing the indirect cells kill effects that could be
taking place with high dose per fraction treatments, even though with residual patient set
up errors. Although these results should not be predictive among all patient cohorts. These
studies also have no documentation of normal tissue toxicities. It must also be noted that
the normal tissue complication probability (NTCP) described in Chapter 6 should also not
be used as a predictive measure. There is controversy on which parameter is best to be used
to predict normal brain toxicity. Whole brain V12 Gy is the most popular in the SRS
community, though V8 Gy, V14 Gy and mean brain dose (MBD) are still worthwhile to
considered. In Chapter 6, V14 Gy was used as a predictive measure of NTCP based on the
most recent research. Milano et al. generated a NTCP model based on the V14 Gy and the
volume corresponding to 50% risk of radionecrosis due to SRS to brain lesions.11 For
consistency with this model, we used the same parameters that this research chose, though
it should be considered that other parameters might have the possibility to better predict
the brain toxicity.

7.3

Future Research Directions
There are several directions this dissertation can be further expanded. There is much

more work to be done on the investigation of the radiobiological response of single fraction
SRS via SIMT VMAT, specifically in terms of indirect cell killing. It would be useful to
report the absolute magnitude of indirect cell death for single isocenter VMAT treatments
in conjunction with clinical follow-up results of patient’s tumor local control and treatment
related toxicity. This has potential to expand and better predict the role that indirect cells
kill could plays in single fraction, high dose treatments, potentially guiding treating
physicians prescribing the most appropriate dose to the lesion. A simplified radiobiological
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model was discussed in Chapter 6 for describing the effects of direct and indirect cell kill.
In reality, they both play a role in different magnitudes for any given doses. Cellular
modeling with SRS could be used to further understand this magnitude of contribution for
both direct and indirect cell death. These contributions can be used to improve the
biological model’s performance in the future for predicting and understanding the role of
indirect cell kill in SRS treatment of multiple brain metastases. This can all be further
expanded by generating a novel model for accurately predicting tumor local control rates
for single fraction treatments of multiple brain metastases. This can then be used to
investigate how residual setup errors affect patient outcomes and potentially be used as a
predictive model for future patient’s treatments.
There is also room to expand the usability of SIMT VMAT treatments in the clinic by
examining the potential for fractionated single isocenter treatments that were traditionally
treated on GK radiosurgery unit. For example, a large tumor bed or larger brain metastases
could be treated in a fractionated treatment scheme with 24 to 30 Gy in 3 to5 fractions,
while managing brain toxicity. There is also potential for larger acoustic neuromas or
meningiomas to be given a fractionated treatment with 25 Gy in 5 fractions and maintaining
brainstem toxicity. This gives potential to reduce side effects on the normal brain and other
immediately adjacent OAR and potentially improve patient outcomes.
As mentioned in Chapters 2 to 4, in the multi-lesions setting, there is a major issue of
higher dose spill to the normal brain due to island blocking between/among the tumors.
This was addressed in Chapter 4 with the dual isocenter approach by reducing the amount
of island blocking, lessening the dose spill between tumors. This can be further moderated
by introducing a new degree of freedom via collimator optimization during gantry
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rotations. In addition to a variable dose rate and gantry speed with continuous gantry
rotation as in standard SIMT VMAT plan, the collimator angle could also vary in an
optimized fashion. This extra degree of freedom could potentially limit the amount of
island blocking and therefore reducing dose to the normal brain.
Recently, Varian HyperArc VMAT has been a major development in Linac-based SRS
programs to treat multiple brain lesions simultaneously. With the results mentioned in
Chapter 3, the novel DCA-based VMAT approach can be adopted and fully automated into
the current geometry that HyperArc VMAT uses. This could further reduce dose to normal
brain and spare other OAR while reducing the total monitor units and ultimately further
improving the beam on time as demonstrated in Chapter 3. It also has less MLC modulation
to minimize the presence of leakage and transmission and improving small field dosimetry
errors.
Finally, there is a potential to further automate the entire course of treatment planning
and delivery for SIMT VMAT SRS for multiple brain metastases. As mentioned above,
Varian Medical Systems developed a prescription-based planning module for single
isocenter VMAT known as HyperArc in the Eclipse TPS (Varian Medical Systems, v 15.6,
Palo Alto, CA). From placement of isocenter and the application of beam geometry to the
virtual “dry run” it is nearly all automated. However, in order to fully automate the planning
process, a knowledge-based planning (KBP) model, such as RapidPlan (Varian Medical
Systems, v 15.6, Palo Alto, CA), could be used to further automate the treatment plan
optimization process.12,13 Full automation of the treatment planning process via KBP model
could further simplify these complex patient’s single isocenter VMAT treatments,
potentially increasing clinic workflow, patient safety and decreasing intraplanar variability.
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7.4

Closing Remarks
This research develops a Linac-based SRS protocol for the fast, safe, effective and

accurate treatment delivery for multiple brain metastases using SIMT VMAT, improving
patient comfort and clinic efficiency. Utilizing these novel patient setup correction
strategies, more accurate SRS treatments could be delivered to multiple brain lesions. It
will open an avenue for patients who cannot tolerate traditionally longer treatment times
or frame-based treatments. It provides treatment availability to those who do not qualify
for GK SRS due to large tumor sizes and critical locations, those who deny WBRT or
patients without access to other SRS treatment options. The findings in this dissertation
provide clear instructions for optimal treatment planning strategies for the treating
physicians and physicists along with simplified patient’s setup instructions for the
therapists. These guidelines can be provided to support other radiotherapy clinics including
community centers who have less or no experience in treating multiple brain metastases.
This dissertation fully explores the clinical usefulness and limitations of SIMT VMAT as
an SRS treatment alternative for multiple brain metastases patients.
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APPENDICES

APPENDIX 1. GLOSSARY
6DOF
AAA
BED
BEV
BOT
CBCT
CGS
CI
CN
DCA
DCK
DVH
EPID
FFF
GK
GTV
HA
HI
ICK
IDV
IMRT
KBP
KPS
Linac
LQ
MBD
m-bm
MBD
MF
MLC
MME
MRI
MF
MU
NTCP
NTO
OAR
PD
PO

Six Degrees of Freedom
Anisotropic Analytic Algorithm
Biological effective dose
Beam’s Eye View
Beam On Time
Cone Beam Computed Tomography
Calculation Grid Size
Conformity Index
Conformity Number
Dynamic conformal arcs
Direct Cell Kill
Dose Volume Histogram
Electronic Portal Imaging Device
Flattening Filter Free
Gamma Knife
Gross Tumor Volume
HyperArc
Heterogeneity Index
Indirect Cell Kill
Isodose Volume
Intensity Modulated Arc Therapy
Knowledge Based Planning
Karnofsky performance status
Linear Accelerator
Linear Quadratic
Mean Brain Dose
Multiple Brain Metastases
Mean Brain Dose
Modulation Factor
Multi-leaf collimator
Multiple Metastases Element
Magnetic Resonance Imaging
Modulation Factor
Monitor Units
Normal Tissue Control Probability
Normal Tissue Objective
Organs at Risk
Portal Dosimetry
Photon Optimizer
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PTV
QA
RPS
RTOG
SIDCA
SIMT
SRS
SSD
STD
TCP
TPS
TV
UR
VMAT
WBRT

Planning Target Volume
Quality Assurance
Recursive Partitioning Analysis
Radiation Therapy Oncology Group
Single Isocenter Dynamic Conformal Arc
Single Isocenter Multitarget
Stereotactic Radiosurgery
Source to Surface Distance
Standard Deviation
Tumor Control Probability
Treatment Planning System
Target Volume
Undertreatment Ratio
Volumetric Modulated Arc Therapy
Whole Brain Radiotherapy
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APPENDIX 2. VISUAL SCRIPT FOR PLAN DATA EXTRACTION
This visual script is useful as a data taking tool from information that can be
found in the dose volume histogram (DVH). The first line of the visual script calculates
the DVH and puts the metrics into a file. The second line allows you to pick which
structure sets and metrics that you want exported. For this dissertation, the PTV and GTV
maximum doses along with hippocampi, brainstem and optic apparatus maximum doses.
The normal brain V8 Gy, V12 Gy and MBD were also exported. The exported files were
placed in a word document that could then be further used in the data analysis process.
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